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1.1. Triple-Negative Breast Cancer 
 
Cancer is an umbrella term for a wide range of diseases, which results from abnormal growth 
and division of the cells. In cancer: cells divide uncontrollably, can be invasive and metastasize 
into adjoining or distant organs [1]. Cancer is the second leading cause of death worldwide [2]. 
Cancer epidemiology varies between sexes and ages. Men are more likely to encounter lung, 
colon, urinary, and obviously prostate cancer. Whereas women are more likely to encounter 
thyroid, breast and lung cancer [3].  
Breast cancer is the most frequent cancer among women, 2.1 million women are impacted each 
year, and also causes the highest number of cancer-related deaths among women [4]. Breast 
cancer is divided into different sub-groups according to the genes that are expressed by the 
specific cancer cells. The subgroups mainly reflect estrogen (ER) and ER regulatory genes 
expressed by the normal luminal epithelial cells. They can either be human epidermal growth 
factor receptor 2 (HER-2) positive, which displays ErbB2 / HER-2 expression and amplification 
or basal that display ER, Progesterone and HER-2 negative expression. Basal breast cancers are 
known to be more aggressive and highly invasive [5].  
One of the major basal-like breast cancer is triple-negative breast cancer (TNBC), which is 
defined by the lack of expression of estrogen, progesterone and HER-2 receptors. TNBC 
represents a percentage of 10 -15 % of all diagnosed breast cancer patients [6].  
The main concern regarding TNBC aggressiveness is its high capability of metastasis. The 
development and progression of the metastasis in TNBC is quite a complex and poorly 
understood process, which includes multiple steps; angiogenesis, genetic and epigenetic 
alterations, tumor-stroma interactions, the cells ability to survive in circulation, the 
extravasation into distant organs, e.g. lungs, bones, and brain, and finally the intravasation 
through the basement membrane [7].  
Patients diagnosed with TNBC have a relatively poor prognosis and outcomes because they 
cannot be treated with conventional therapies targeted to HER-2 or endocrine therapies. As a 
consequent, this type of cancer requires special and innovative treatment approaches. Moreover, 
the overexpression of EGFR protein in TNBC usually increases its resistance to conventional 
therapies [8].  
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1.2. Doxorubicin for cancer therapy 
 
The frontline drug doxorubicin (DOX) has been available in the market for treating cancer for 
over 30 years. While providing a wide cure range in multiple cases, DOX causes toxicity to 
most major organs, importantly the life-threatening cardiotoxicity [9]. Cardiotoxicity forces the 
treatment with DOX to be dose limited.  
DOX belongs to nonselective class I anthracycline antibiotics, which is derived from the 
actinobacteria Streptomyces peucetius var. caesius [10]. DOX, a hydroxylated daunorubicin 
derivative, is available in the market under the name adriamycin, possessing sugar and 
aglyconic groups (Figure 1).  
 
 
 
Figure 1: Chemical structure of Doxorubicin (DOX), DOX is a nonselective anthracycline. 
DOX is composed of two main parts aglycone part and a sugar part also known as 
daunosamine, and it is attached to the glycone part by a glycosidic bond [11].  
 
The ability of DOX to combat rapidly dividing cells and slow cancer progression has provided 
it as one of the most potent Food and Drug Administration (FDA) approved chemotherapeutic 
agents [12]. DOX binds to DNA-associated enzymes, targets several molecular targets for 
cytotoxicity, disrupts the topoisomerase-II-mediated DNA repair and can as well intercalate 
with DNA base pairs [11]. DOX exacerbates the apoptosis pathway by activation of several 
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molecular signals from AMPK (AMP-activated protein kinase) to enhancing the Bcl-2/Bax 
apoptosis pathway [13]. DOX does not selectively affect cancerous tissues, it induces apoptosis 
in various healthy tissues (lung, liver, brain, kidneys, and heart). Therefore, many studies have 
been conducted over the years to incorporate DOX into various drug delivery systems (DDS) 
including liposomes, nanoparticles and hydrogels.  
Apoptosis occurs when DOX enters the cell through diffusion as in its free form, or other 
endocytotic pathways in its nanoscale carriers form. Firstly, DOX binds to the cytoplasm´s 
proteasome afterward DOX-proteasome complex is formed and translocated through the 
nuclear pore into the nucleus. DOX has a higher affinity towards nuclear DNA than to the 
proteasome, therefore, it dissociates from the proteasome to bind to nuclear DNA [11]. 
Additionally, DOX generates free radicals causing further DNA damage, DNA separation and 
increasing alkylation and inhibition of macromolecules production [14]. Furthermore, DOX can 
bind to plasma proteins causing enzymatic electron reduction of DOX thus affecting the cell 
membrane directly. The oxidized form of DOX, semiquinone- an unstable metabolite- is 
converted back to DOX in a process that releases reactive oxygen species (ROS), which 
promote a cascade of free radicals formation that leads to lipid peroxidation, membrane 
damage, DNA damage, and eventually triggers apoptotic pathways of cellular damage. This 
effect can cause the formation of greatly reactive free radicles. The formation of the highly 
reactive free radicles is responsible for cytotoxicity elicited by the use of DOX, though these 
same mechanisms of action make DOX an efficient anticancer agent against various types of 
cancer [15].  
The specific pathway of cell death caused by the administration of DOX varies depending on: 
a) concentration of DOX, b) treatment duration, c) a specific form of cancer and the multidrug 
resistance-associated with that specific cancer type.  
Moreover, the main drawback of DOX administration is DOX- associated cardiotoxicity mainly 
due to cardiomyopathy caused by prolonged exposure to the formed free radicals. To overcome 
this toxicity, DOX was encapsulated into the first FDA-approved PEGylated liposomes called 
Doxil® / Caelyx ®, the liposomal formulation has decreased the toxicity associated with DOX 
treatment [16]. 
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1.3. Targeting 
   
The concept of drug targeting was firstly introduced in the early twentieth century by Paul 
Ehrlich under the name “magic bullet”, in which an increased accumulation of pharmaceutically 
active ingredients (PAI) is accumulated in the required tissue or organ in the body. However, 
this concept was not fully applicable to most of PAI in the market as the drug accumulation in 
the diseased organ is highly dependent on the pathological processes or on biological pathways. 
The concept of drug targeting re-emerged with the investigation of the cancer tumor nature and 
the utility of nanocarriers for cancer treatment. 
 
 
1.3.1. Passive targeting 
 
The tumor endothelial lining of the blood vessel walls is more permeable than in the normal 
blood vessels (Figure 2). This is a confirmed phenomenon and is clearly demonstrated and 
reported in many tumors [17,18]. As a result of this phenomenon, in the tumor areas, nanoscale 
carriers can accumulate into the interstitial space. The nanoscaled carriers are loaded with PAI, 
where they bring these active agents to the area with thining vessels and increased permeability 
and subsequently, the active pharmaceutical agent is released from the nanoscale carrier into 
the interstitium. Moreover, because the cut-off size of the permeabilized vessels differs from 
one tumor to another [17,18], the size of the nanocarrier may play a crucial role in the efficacy 
of such unforced “passive” DDS. The effect in which these nanoscaled carriers of a specific 
size are permeabilized into the vessels and are accumulated in the tumors is referred to as 
Enhanced Permeability and Retention effect (EPR) (Figure 2)[19]. The EPR effect requires long 
circulation nanocarriers thus the incorporation of polyethylene glycol (PEG) grafted to the 
surface of these nanocarriers and prevented their rapid clearance by the reticuloendothelial 
system [20]. The prolonged circulation of the nanocarriers is advantageous due to the possibility 
of maintaining the required concentration of PAI after a single dose only, as well as the 
possibility to enhance the targeting into the tumor interstitium with limited blood supply. 
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Figure 2: Schematic representation of the EPR effect (passive targeting in cancer tissue). 
 
1.3.2. Active targeting  
 
Since the EPR is dependent on the poor integrity of vascular endothelium, it is hampered, where 
the vasculature integrity remains unaffected. There are many approaches for drug targeting 
including the utilization of temperature, pH, or magnetic targeting. However, these are not 
universal. In some tumors, the affected area does not differ from the normal tissue regarding 
vascular permeability, local pH or temperature. Magnetic drug targeting is often restricted by 
the efficient blood flow rate in the targeted area. Thus decreasing the efficiency of passive 
targeting. Therefore, active targeting comes as an urgent need as the most universal and natural 
way for a nano specific drug affinity. Active drug targeting requires the surface modification 
of the nanocarrier (e.g., liposomes) with a targeting moiety that is capable of specific and 
selective recognition and binding to the targeted site (Figure 3). This mechanism depends on 
the interaction between tumor ligands conjugated to the surface of nanocarriers and cell-surface 
receptors or antigens on cancer cell surfaces. Targeting moieties can differ between antibodies 
or antibodies-fragments, proteins, lipoproteins, hormones, aptamers, mono-, oligo-, and 
polysaccharides, hormones, lectins, and some other ligands, e.g. folate [21]. A number of 
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nanocarriers formulations have been developed for the active targeting purpose to improve 
anticancer efficacy and to reduce side effects. 
 
Figure 3: Schematic presentation of active targeting. With anti-ADAM8 antibody MAB 1031- 
modified liposomes bind to the overexpressed ADAM8 antigen on the cellular surface. 
 
1.4. Liposomes 
 
The discovery of liposomes in the mid-1960s [22] and their similarity to cell membranes 
introduced cell biologists with a convenient tool to study cell membrane functions. However, 
the actual consideration of liposomes as a candidate for drug delivery of PAIs was not until 
several years later in the 1970s [23,24]. Liposomes are vesicles that vary in size between 25 nm 
to 2500 nm [25]. Several factors define liposomes properties: i) lipid composition, normally 
liposomes are composed of phospholipids, and they may include other lipids. The membrane 
encloses an aqueous core that can be used to encapsulate hydrophilic drugs, whereas lipophilic 
drugs can be incorporated into the liposomal membrane [26]. ii) The number of the lipid bilayer; 
either unilamellar (consisting of a singular phospholipid bilayer) or multilamellar (consisting 
of two or more separated by water) [27]. iii) Size, surface charge, and the method of preparation 
are as well crucial factors affecting the liposomal vesicles half-life as well as the quantity of the 
active ingredient being encapsulated [25].  
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Recent advances in biomedical and pharmacological sciences facilitate the design and synthesis 
of a wide range of new agents with potential activity against a high number of therapeutic 
targets in vitro, especially cancer treatment. Many cytotoxic agents were quite successful            
in vitro, however, the clinical translation of these agents failed for numerous bioavailability 
related reasons: a) the inability to reach therapeutic concentrations in the active site, b) the 
nonspecific cytotoxicity affecting bone marrow, GI, renal and cardiac tissues (e.g. dose-related 
cardiac toxicity associated with DOX treatment), or problems related to the drug itself, i.e. 
problems related with the stability, solubility or other formulation related problems [28]. To 
overcome these drawbacks, cytotoxic agents can be encapsulated into liposomes, to minimize 
the side effects and enhance their therapeutic index without compromising the antitumor 
efficacy [29]. Liposomes allow the transportation of cytotoxic agents and protect them from 
degradation [30]. They pertain distinctive features that make them suitable for drug delivery: 
they are biodegradable, non-toxic, biologically inert, stable within biological environments, 
show controllable release behaviors i.e. triggered release by temperature, pH or others and are 
biocompatible. The possibility of coating their outer membrane with long polymer chains such 
as polyethylene glycol (PEG) that make them stealthier and prolong their circulation time 
[25,31]. 
 
 
1.4.1. Preparation of liposomes and DOX remote loading  
 
The method of liposomes preparation affects its size, lamellarity, shape, and encapsulation 
efficiency of the loaded drug. Therefore, addressing the preparation method in advance is 
essential to reach the desired liposomal properties.  
Conventional methods for preparing small and large unilamellar vesicles (SUVs and LUVs) 
are: 
A) Injection of organic solvent with dissolved phospholipids into an aqueous phase [32,33]  
B) Reverse phase evaporation [34] 
C) Detergent dialysis [35,36]. 
Conventional methods for preparing multilamellar vesicles (MLVs) are categorized into these 
main methods:  
A) Hydration of a phospholipid film under hydrodynamic flow [37] 
B) Solvent spherule method [38] 
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C) Hydration of stable, dry, free-flowing granular composites containing a phospholipid 
and a carrier/drug (Proliposmes) [39] 
D) Thin-film hydration, his method involves obtaining a thin lipid film in a round-bottom 
flask by the removal of organic solvent, usually in a vacuum evaporator. Upon the 
addition and agitation of the dispersion aqueous medium, heterogeneous liposomes are 
formed [40].  
The formation of MLVs is easily achieved spontaneously, various techniques such as 
sonication, homogenization and membrane extrusion are often used to convert the MLVs into 
SUVs and LUVs.  
One of the major hurdles in the pharmaceutical application of liposomes is their efficient and 
stable loading with the pharmaceutically active ingredients. This is of special importance when 
liposomes are of small size [41]. DOX is preferentially delivered to the tumor site using 
liposomal-DOX, it has been previously reported that liposomal associated DOX drug delivery 
systems improve the therapeutic index by increasing the cumulative dose of DOX treatment 
with reduced cardiac toxicity [42,43]. Therefore, obtaining a method able to load a higher 
amount of DOX with the associated liposomal DOX decreased toxicity is highly desirable. 
There are four reported strategies for efficient drug loading, which are driven by the use of    
pH-, sulfate-, manganese- or citrate-gradient. Bahrenholz and his working group were the first 
to achieve a method for efficient DOX loading using ammonium sulfate [44]. The method was 
fast, resulted in stable liposomal vesicles when stored up to two years. Effective and applicable 
for liposomes prepared by different preparation methods, not affected by the liposomal lipid 
composition as well as applicable for various drugs with the same physiochemical properties 
(amphipathic weak bases) [44]. Mainly all drug loading techniques follow the same principle, 
i.e., the free DOX amphipathic base diffuses into the liposomal payload using a specific 
gradient. This modification of DOX occurs due to the salt present in the payload which prevents 
the membrane permeation, results in the accumulation of a sufficient amount of DOX inside 
the liposomes. Figure 4 represents the intraliposomal remote loading of DOX by mean of an 
ammonium sulfate gradient between the intraliposomal aqueous payload and the external 
medium. 
Ammonia efflux is the main driving force for the influx of the amphipathic base (DOX), it 
produces a [H+] gradient, where [H+] in liposomes > [H+] in the medium. Unprotonated DOX-
NH complex crosses the liposomal membrane and therefore is then protonated [45]. In the 
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presence of SO4
-2 a gel-like precipitate is formed [46], thus entrapping the DOX in the aqueous 
phase of the liposomes without re-permeation to the surrounding medium. 
 
 
Figure 4: Remote loading of DOX into liposomes via ammonium sulfate gradient method. 
 
1.4.2. Thermosensitive liposomes and DOX triggered release 
 
The majority of the liposomal drugs are formulated in an intention to remain permanently 
entrapped in the liposomal carrier upon systematic administration and following circulation.  
98 % of reported DOX PEGylated liposomes remained entrapped during the circulation up to 
7 days [47,48]. This contributes to the observed desirable pharmacokinetics of DOX PEGylated 
liposomal formulations as most, if not all liposomal drug will remain restricted to the blood 
circulation, which will cause a low volume of distribution in comparison to the free drug. On 
one hand, a stable DOX entrapment prevents major cytotoxicity, i.e., cardiotoxicity. On the 
other hand, this feature regarding DOX PEGylated liposomes circulation has turned out to be a 
major drawback after arriving at the tumor, where supposedly DOX become bioavailable to the 
tumor cells highly stable DOX formulations, this feature is severely hampered.  
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Moreover, the efficiency of DOX treatment is directly related to its cumulative dose within the 
tumor. The conventional nanocarriers based DDSs aim to release the encapsulated DOX as soon 
as the nanocarrier reaches the tumor [49]. Where the tumor is exposed to inadequate 
concentrations of DOX over a long period of time, thus increasing the probability of tumor 
developing multi-drug resistance (MDR) [50]. Long story short, as a result of slow 
accumulation of the liposomal DOX in the tumor in combination with the instant release, the 
concentration of the existing concentration of DOX in the tumor will increase gradually 
proportional to the liposomes concentration. Therefore, the tumor is exposed to DOX 
concentration in the sub-lethal concentrations < LD50 throughout the accumulation time in vivo 
(24 h) [51], and this will increase the likelihood of developing MDR.  
Moreover, to overcome the abovementioned drawbacks regarding DOX release, Yatvin et al. 
introduced the first thermosensitive liposomes, that remain intact in the physiological 
temperature and prevent premature leaking and subsequently release the encapsulated drug 
upon triggered release caused by external hyperthermia [52]. Gaber et al. introduced the first 
thermosensitive DOX liposomes, thus allowing the concentration of DOX to reach higher 
concentrations the sub-lethal dose > LD50 [53]. Yatvin et al. introduced pH-sensitive liposomes 
to elevate DOX release using the advantageous acidic surroundings in the solid tumor [54]. 
However, these liposomes were shortly introduced with a major drawback regarding DOX 
encapsulation due to their low pH payload which prevented adequate DOX loading using pH 
gradients. Thereafter, the best approach for the delivery of an adequate concentration of 
liposomal DOX is the utilizing of thermosensitive liposomes.  
DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) is the most reasonable lipid that is used 
in thermosensitive liposomes since it is has a phase transition temperature of Tm = 41 °C. Phase 
transition temperature represents the temperature required to transfer from liquid condensed to 
the liquid expanded phase of the lipid mixture of the liposomes. By incorporating DSPC  
(1,2-distearoyl-sn-glycero-3-phosphocholine, Tm = 56 °C) with various proportions, one can 
obtain any phase transition temperature between 41 – 56 °C. Both lipids are quite miscible and 
after differential scanning calorimetry analysis only single-phase transition temperature is 
observed [52]. Moreover, DPPC is adopted as the main lipid of all reported thermosensitive 
liposomes [53,55-57]. Gaber et al. reported stealth DOX thermosensitive liposomes containing 
DSPE-PEG as well as cholesterol beside DPPC and DSPC with 50 % of DOX released after 30 
min of heating at 42 °C [53]. Although they have obtained very promising results in vitro, no 
in vivo translation was additionally investigated. 
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Furthermore, recently thermosensitive DOX liposomes importance has risen in the nanocarrier 
research field with the new developed most studied thermosensitive liposomes (ThermaDOX®).  
The intravascular release refers to an approach in which the main site of the DOX release takes 
place within the blood vessels of the tumor [58]. Prior to the treatment, the tumor site is ensured 
to reach physiological temperature or in some cases, it is heated to an appointed temperature, 
once thermal equilibrium is established, DOX liposomal formulation is injected. The DOX 
formulation aims to destroy the endothelial vasculature of the tumor that is located in the 
previously heated sites. Some of the most used methods for heating are water bath heating, 
where this method offers a higher accumulation in tumor vasculature [57] and the released DOX 
at the heated area is able to damage the vessels that nourish the tumor [58]. The heating using 
a water bath showed successful results in vitro, which offer higher initial plasma vesicle DOX 
concentrations and higher vascular permeability. However, heating by water bath is 
inapplicable in vivo, the utility of clinically available methods for heating, i.e. radiofrequency 
(RF), high intensity focused ultrasound (HIFU), have been heavily studied and investigated due 
to fulfill the urgent need. 
 
 
1.4.3. Phase transition temperature of liposomes  
 
The fundamental principle behind drug release from thermosensitive liposomes is the transition 
from liquid condensed phase to liquid expanded phase at the subtle blend of phospholipid’s 
specific temperature (Figure 5). The transition between these phases is driven mainly by the 
gain of configurational entropy of the thermodynamic system; mainly the entropy of the acyl 
chain of the phospholipid.  
It can be measured by different techniques, fluorescence spectroscopy, infrared spectroscopy, 
nuclear magnetic resonance (NMR), and differential scanning calorimetry (DSC) [59]. DSC is 
the main method used to measure endothermic and exothermic responses within a material, here 
phospholipids, at a designated temperature. There are three main parameters in the DSC 
thermogram i) the pretransition temperature, which represents the temperature between liquid 
condensed and liquid expanded phase of the phospholipids. ii) the maximum phase transition 
temperature (Tm), in this phase the major transition occurs, where it is dependent on the 
conformational alignments of the acyl chains in the tail group of the phospholipids allowing 
maximal van der Waals interactions between molecules. iii) the area under the curve is a 
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proportional relation to transition enthalpy (ΔH), which represents the energy required to melt 
the acyl bonds in the tails of the phospholipids [60,61].  
 
The thermodynamic driving force that determines the phase transition temperature is 
illustrated by the Gibbs free energy equation (ΔG): 
 
𝛥𝐺 =  𝛥𝐻 − 𝑇ₘ 𝛥𝑆                                                    Equation 1 
 
Where ΔH = enthalpy change, Tm = phase transition temperature, ΔS = entropy change. 
 
At an equilibrium phase ΔG = 0, thus the enthalpy change is given by 
 
𝛥𝐻 =  𝑇ₘ 𝛥𝑆                                                                  Equation 2 
Tm is measured by: 
𝑇ₘ =  
𝛥𝐻
𝛥𝑆
                                                                          Equation 3 
 
 
 
 
 
Figure 5: Phospholipid bilayer membrane phase stages upon heating. The phospholipid bilayer 
is in the liquid condensed phase (T < Tm), it changes to liquid expended phase after the melting 
of head and chain groups at (T > Tm). During the phase transition, the membrane shows a high 
permeability. 
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1.4.4. Paramagnetic thermosensitive liposomes 
 
Thermosensitive liposomes, which are mainly composed of DPPC enhance the payload release 
near the phase transition temperature of the liposomes. There are numerous attempts to develop 
new thermosensitive liposomes to improve their thermosensitivity and thermal response. The 
incorporation of a heat-responsive substance such as polymers [62] or heat-inducing material 
that generates heat as a response to an external source such as laser [63], ultrasound [64] or 
magnetic field [65] can elevate the temperature allowing the triggered release of 
thermosensitive liposomes cargo.  
One of the recent updates of the innovative thermosensitive liposomes formulations is including 
HIFU, RF and alternating magnetic field (AMF). 
Of most concern to use here are paramagnetic liposomes as MRI contrast agents developed for 
both imaging-guided DDS and the hyperthermia to open the thermosensitive liposomes and 
released of the drug (Figure 6). Assessed triggered release from the thermosensitive liposomes 
is to be discussed later. The paramagnetic liposomes could be developed by the incorporation 
of Gadolinium- chelate (Gd-chelate) in the liposomes [66,67]. 
The encapsulation of paramagnetic compounds, especially Gd-chelate, usually results in an 
evident reduction in relaxivity (r1) as the magnetic interaction with the surrounding water 
protons becomes limited by the restricted permeability of the water protons through the lipid 
bilayer of the liposomes [68]. Hence, the increase of R1serves as an indication of the successful 
release of the encapsulated cargo.  
 
Figure 6: Schematic presentation of DOX release from the magnetic thermosensitive liposomes 
upon hyperthermia under UHF-MRI exposure. 
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1.4.5. Immunoliposomes 
 
The concept of targeted DDS has long teased scientists in many fields, perhaps in most cancer 
treatment fields. Immunoliposomes represents a logical strategy to achieve targeted DDS in 
cancer treatment. However, despite decades of preclinical investigation, immunoliposomes 
have yet to appear more promising to be evaluated in clinical trials. Currently,                                   
15 immunoliposomes formulations are approved in clinical oncology [69]. Early attempts to 
develop immunoliposomes as a targeted DDS faced several obstacles involving the 
immunoliposomes constructions: identifying the target antigen, antibody, antibody-liposomes 
linkage, liposomes composition, structure and functionality and the drug encapsulated.  
Furthermore, immunoliposomes represent an advanced strategy to enhance liposomal DDS, by 
linking liposomes to monoclonal antibodies (MAbs), which are directed against tumor antigens. 
Most tumor-chosen antigens are overexpressed on tumor cells contrary to normal cells. 
However, the overexpression of the tumor antigen does not occur homogeneously in all the 
cancer cells, thus giving an obstacle for the immunoliposomes to target the required antigen 
[70]. Additionally, the site-specific targeting offered by immunoliposomes can increase the 
therapeutic efficacy and decrease the cytotoxicity. In order to obtain a liposomal targeting 
system, an antibody has to be conjugated to the surface of the liposome [71]. Several methods 
for the antibody conjugation were reported, mostly differing in their chemical basis [72-74]. 
However, these liposomes were of a limited benefit due to their rapid circulation clearance, the 
introduction of PEG prolonged the liposomes circulation and helped to enhance targeting.  
For the targeting experiments, it is essential to obtain a successful surface modification of the 
liposomes. A suitable anchor is an essential factor in the modification process. A method of 
rapid and simple coupling is of great importance in our research. Furthermore, a rapid method  
of coupling of the antibody at the end-group of a derivatized PEG with cyanuric chloride was 
firstly introduced by Bendes et.al and his working group and is currently commercially 
available [69,75]. This method needs only a few preparative steps and is feasible without prior 
manufacturing processes. The cyanuric group enables antibodies conjugation without any prior 
derivatization [75]. A great advantage of this form of binding is its simplicity. Additionally 
being very cost-effective especially when using sensitive and expensive targeting moieties such 
as antibodies. 
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1.5. Ultra high field magnetic resonance imaging 
 
Ultra high field magnetic resonance imaging (UHF-MRI) is a non-invasive imaging technique 
that produces three-dimensional anatomical images. It is a powerful technique in diagnostics, 
disease detection as well as treatment monitoring. MRI was firstly introduced by Paul C. 
Lauterbur in 1973 when he has published images represent the Nuclear Magnetic Resonance 
(NMR) response of the hydrogen nuclei in a pair of water glass capillaries [76]. Only 1-D 
projections could be obtained while applying a magnetic field in various directions. Soon after, 
Peter Mansfield introduced a method to acquire efficient images, including slice selection [77]. 
Afterward, fast acquisition schemes were developed, where entire 2-D images could be 
acquired within a few tens of milliseconds [78]. 
MRI was restricted to laboratory use in its first years of discovery and its application flourished 
into the market after a postdoctoral fellow implemented Fourier (spin-wrap) imaging and could 
acquire the first clinically useful image of a human subject [79]. Over the last few decades, MRI 
tests and images have become widely used as a routine diagnostic procedure. It is estimated 
that the number of scans performed every year exceeds 100 million [80]. MRI technology is 
moving towards a large installed base of 7 T (Tesla) systems. New MRI scanners are equipped 
with ultra high magnetic fields (UHF) ≥ 7 T. There are some other trends regarding MRI 
application, such as the combination of Positron emission tomography (PET) and MRI and the 
integration of soft tissue imaging of MRI with other noninvasive procedures, i.e. MR-guided 
focused ultrasound.  
MRI employs a powerful magnetic field that forces protons in the body to align with the given 
field. It is based on a sophisticated technology that excites and detects the change in the 
direction of the proton´s rotational axis of those protons found in water that makes up the 
tissues. 
MRI is considered the most complex imaging technology in the market. Whereas most imaging 
techniques portray differences in one, or sometimes two, tissue characteristics, MR depicts five 
tissue variables; i) spin density, ii) T1 and iii) T2 relaxation times, iv) flow and v) spectral shifts. 
These variables can be combined in several ways through selecting puls sequence and puls time 
[81]. The most interesting characteristics in DDS research are T1 and T2 relaxation times.  
Relaxation defined as the process in which spins release the energy received from a 
radiofrequency pulse. T1 relaxation time, also known as spin-lattice or longitudinal relaxation 
time, is a measure of how quickly the net magnetization vector recovers to its ground state in 
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the direction of the offset frequency (static magnetic field) B0 [82]. The recovery of the excited 
nuclei from the high energy state to the low energy state is associated with loss of energy to the 
surrounding nuclei. NMR was used originally to examine solids in the form of a lattice, hence 
the term “ spin-lattice” relaxation [83].  
T2 relaxation, also known as spin-spin or transverse relaxation time, represents the progressive 
dephasing of the spinning dipoles after the 90 ° pulse as illustrated in a spin-echo sequence due 
to tissue-specific characteristics, especially those that affect the rate of proton´s movement, 
most of which are found in water molecules [84]. Another term that is common when describing 
relaxation is the relaxation rate (R), which refers to the reciprocal of the T1 or T2 time 1/T1 
(R1) or 1/T2 (R2). T1 relaxation is the fastest when the rotation and translation of the nucleus 
match that of Larmor frequency (Larmor frequency represents a phenomenon when a magnetic 
moment is placed in a magnetic field it will tend to align with the field). Subsequently, T1 
relaxation is dependent on the magnetic strength of Larmor frequency. Therefore, a higher 
magnetic field means higher T1 relaxation times [85].  
R1 and R2 of the nuclei of liquids characterize the rapidity with which a thermodynamic group 
of similar nuclei achieves thermal equilibrium. For partially deuterated water, i.e., every proton 
must be coupled to a thermal background, “the lattice” mentioned earlier, through a noisy 
interaction that is modulated by Brownian thermal motion, which transfers the lattice 
temperature to the nuclear ensemble. Moreover, the motional narrowing described by 
Bloembergen [86] and Solomon [87] dominates the relaxation. Briefly, a given water molecule 
senses the local dipolar magnetic field that is generated by a nearby water proton and a rapid 
rotation and translation of water molecules occur.  
 
1.5.1. Contrast agents 
  
Contrast agents are widely used in MRI. The most dominant contrast agent in clinical 
applications of MRI is gadolinium-based (Gd) T1 contrast agents, which strongly increase 
signal intensity on T1-weighted images, shorten images acquisition time, and thereafter 
improve diagnostic confidence. Contrast agents are mainly characterized by their relaxivity (r1 
and r2), which as abovementioned is defined as the change of relaxation rate of solvent water 
protons upon the addition of contrast agents. Another clinically used T1 contrast agent is 
manganese, however, is it not as commonly used as Gd-based T1 contrast agents as the research 
on this agent is still at an early stage [88]. Iron oxide [89] and iron platinum [90] are T2 contrast 
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agents, which enhance the T2-weighted images. However, these two agents were withdrawn 
from the market on the basis of safety issues [91].  
Gd(III) is a lanthanide metal that occurs usually in a water-soluble salt that is very toxic to 
mammalians, one of the well-known factors related to Gd3+ toxicity is its similar size and 
competition with Ca2+ in cellular processes. Gd3+ is capable of inhibiting voltage-gated and 
stretch-activated calcium channels. Thereafter, Gd3+ can cause inhibition of crucially vital 
physiological processes associated with muscle tissue functionality and neurons. Gd3+ can as 
well block Ca2+ dependent enzymes [92,93].  
Chelation has been used in medicine to treat acute metal poisoning or chronic metal exposure. 
Chelation is defined as a chemical procedure in which a chemical chelating agent is utilized to 
bind metal ions, resulting in the formation of metal chelates that are easily eliminated from the 
body. To overcome free Gd3+ toxicity and to benefit from its feasibility as a contrast agent, free 
Gd3+ is chelated with multiple chelating agents. The most common chelating agents for Gd3+ 
are either macrocyclic chelating agents, e.g. tetraazacyclododecane tetraacetic acid (DOTA), or 
linear chelating agents, e.g. diethylenetriaminepentaacetic acid (DTPA). Gd-DTPA is 
commercially available as the widely used Gd-chelate contrast agent Magnivest®. While free 
Gd3+ is highly toxic, Gd-chelate contrast agents have been listed as nontoxic according to FDA 
(FDA 3/16/2018). However, some reports have linked a rare medical event with Gd-chelate. 
Gd-chelates were mentioned as the cause of Nephrogenic Systemic Fibrosis (NSF), which is a 
potentially fatal medical case that causes the hardening of the skin and internal body organs 
[94]. Moreover, Gd-chelate is excreted by the kidneys, individuals with underlying kidney 
problems should obtain extra care. New reports have suggested that Gd-chelate may cause 
nephrotoxicity. Thereby, excessive hemodialysis after exposure to Gd-chelate is advised in 
individuals with endangered renal profile [95].   
Furthermore, T1 relaxation of tissue and blood increases with the increasing magnetic field. For 
a contrast agent with equal r1 at two fields, the T1 change would be higher at the greater field 
because of the inherent tissue R1 is slower at higher field. This is true for commercial 
extracellular agents like widely used Gd-DTPA, where its relaxivity is fairly independent of the 
magnetic field [96].  
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1.5.2. Image-guided drug delivery system 
 
Imaging plays a crucial role in the preclinical evaluation of nanomedicine based DDS. It has 
laid out important insight into their mechanism of action, pharmacokinetics and biodistribution 
destiny, provided a deeper understanding of their therapeutic effect, and their accumulation at 
the target site and in vivo drug release characteristics. Its main role is to support the clinical 
development of nanomedicine DDS and utilize them for the market. 
Recently, image-guided DDS, which supports clinical imaging modalities for guidance and 
regulation of DDS, have heavily emerged as a feasible strategy for enhancement of targeting 
and personalized DDS therapy [97]. In the DDS paradigm, imaging mediated DDS may be used 
to identify targeted and non-targeted anatomies by the used nanocarrier, which may as well help 
with monitoring, planning, and postprocedural assessment of the target as well as provide a 
deeper understanding of the treatment outcome.  
At the preclinical level, image-guided DDS is mainly used for noninvasive visualization and 
quantification of the behavior of nanocarriers upon administration. MRI is particularly used for 
such purpose because of its ability to obtain images and quantitative measurements of a high 
spatiotemporal resolution during therapy. Diffusion-weighted magnetic resonance imaging 
sequence (DW-MRI) is applied to generate high-quality images. The DW-MRI is mainly 
identified as the use of specific MRI sequences that facilitate the generation of images, which 
uses the diffusion of water molecules [98]. This enables the longitudinal assessment of the 
nanocarrier accumulation at the pathological sites, i.e., tumors, metastases, and inflammatory 
lesions. Additionally, endangered off-target cells and tissues can be visualized. By the 
incorporation of imaging in DDS, more meaningful information can be obtained. Imaging 
enables the direct comparison of several materials within a single preclinical subject. This 
characteristic minimizes the variability in the target site as a result of preclinical subjects 
differences in e.g. tumor size, immune response, tumor vascularization. This allows insight for 
personalized medicine and personalized comprehensive understanding of DDS behavior 
subject's body in the era of personalized medicine [99]. 
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1.5.3. Hyperthermia-mediated drug delivery 
 
Hyperthermia in DDS refers to the application of heat from various sources resulting in heat 
temperature higher than normal physiological temperature. Hyperthermia in DDS is generally 
divided into two main categories, mild ( ~ 40 – 45 °C) or ablative ( 50 – 100 °C) [97]. It is 
usually obtained from radiofrequency [100], microwaves [101], or laser [102]. Ablative 
hyperthermia is used to destroy the tumor and reduce its growth in regions of sublethal margins. 
Mild hyperthermia is used mainly to trigger the release of the drug from a thermosensitive 
carrier.  
Moreover, RF is applied in MRI measurements, wherein this technique has been under 
investigation to evaluate its safety to the normal tissues. After the introduction of ultra high  
field MRI, this topic has reemerged and gained higher importance in the research. Increasing 
the magnetic field strength changes the interaction between the applied RF field and the tissue. 
The higher frequency applied due to a higher field shortens the wavelength, thus leads to more 
noticeable local interactions [103]. Moreover, this pronounced interaction between the RF and 
the tissue is translated into thermal energy, reports have observed an increase of about 1-2 °C 
[104-106]. Consequently, the increased temperature during MRI measurements was utilized to 
induce mild hyperthermia to our DDS.  
 
1.6. ADAM8 targeting with modified liposomes 
 
1.6.1. Disintegrin and metalloproteinase domain 8 (ADAM8) 
 
ADAM8 is a transmembrane protein belongs to a disintegrin and metalloproteinase family 
(ADAMs), which obtains a domain-containing protein 8, ADAM8 was firstly identified by 
Yamamoto´s group in Japan. It was described as cDNA cloned from mouse monocytes cell 
lineages [107]. It is a protein that is composed of 824 amino acids, 637 amino acids from the 
extracellular matrix, 16 amino acids form signal peptide, 25 amino acids build the 
transmembrane region, and 146 amino acids that are in the cytoplasmic region, which are of 
great importance because have the Src homology 3(SH3) binding domain. ADAM8 and its 
corresponding family (ADAMs) mediate cell adhesion, proteolysis of various substrates, i.e., 
cytokine receptors, cell adhesion molecules and extracellular matrix components, as well as 
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promote cell migration [108]. ADAM8 can either dimerize or multimerize and autocatalytically 
hook off its domain, resulting in an active membrane-anchored metalloprotease.  
ADAM8 is activated by autocatalysis in the trans-Golgi stack [109]. The activated ADAM8 
can additionally be processed by the release of the metalloprotease domain into the extracellular 
matrix leaving residues from within the membrane (Figure 7). Both active and residual forms 
of ADAM8 mediate cell adhesion throughout their disintegrin/cysteine-rich/EGF-like domains 
[109], mainly by direct binding to integrins [110].  
Active ADAM8 has no essential role under normal physiological conditions [111,112], despite 
its expression in multiple immune cells. ADAM8 is detected under multiple pathological 
conditions, including inflammatory diseases and cancer [108]. Wang et.al have found that 
ADAM8 is overexpressed in aggressive forms of breast cancer, including TNBCs, and is 
correlated with poor prognosis and very poor patients outcomes. In their research, ADAM8 was 
found to promote TNBCs metastases, in which ADAM8 promotes tumor growth and 
angiogenesis and the spreading of circulating tumor cells. Therefore, ADAM8 is a promising 
target for the treatment of TNBCs up to the metastatic cells [113].  
Moreover, using an antibody-based carrier to target ADAM8 is counted as an effective 
therapeutic intervention for the identification, targeting, and treatment of TNBC [114]. 
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Figure 7: Schematic representation of ADAM8, the disintegrin domain is required for 
autolysis. The majority of ADAM8 proteins are processed in the cell membrane. This suggests 
that the extracellular shedding of other membrane proteins occurs mainly on the cell surface, 
thereafter, proteases release into the extracellular compartment resulting in extracellular 
matrix remodeling [115].  
 
 
1.6.2. MAB 1031 antibody modified liposomes for ADAM8 targeting 
 
The targeting of surface structures on tumor cells with actively addressed liposomes is a very 
promising method for both diagnostic and therapeutic strategies. As abovementioned, ADAM8 
is a promising novel target for the diagnosis and treatment of several tumors including TNBC. 
ADAM8 is an extracellular shedding metalloprotease making it a promising target for antibody 
modified liposomes. One of the reported strategies to actively target ADAM8 is by MAB 1031 
antibody [116] (Figure 8), which is a monoclonal mouse IgG2B clone [117]. MAB 1031 
antibody can directly detect ADAM8 and suppress its catalytic activation, thus inhibiting the 
metastatic cascade corresponding with ADAM8 overexpression. MAB 1031 mainly detects an 
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epitope within a specific domain (aa 201-487) (metalloprotease and disintegrin domain) of the 
recombinant human ADAM8. As mentioned earlier, MAB 1031 requires an anchor for the 
successful binding to the liposomal cell surface.  
 
 
 
 
Figure 8: Schematic representation of MAB 1031 antibody (anti-ADAM8 antigen). MAB 1031  
detects an epitope within a specific domain (aa 201-487) (metalloprotease and disintegrin 
domain) of ADAM8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
 
1.6.3. Aim and objectives 
 
The work presented in this thesis aimed to develop a suitable liposomal nanocarrier for DOX, 
that obtains thermosenitive characteristics that would allow the release of the loaded cargo 
DOX by hyperthermia triggered release. Moreover, the heat required for the triggered release 
of DOX from the liposomes is acquired from RF during UHF-MRI. Gadolinium chelate was 
incorporated into the liposomes to achieve both an imaging mediated drug delivery system as 
well as provide diagnosis of the tumor cells in their solid tumor form as well as their circulating 
form. Therefore, liposomes were surface modified with anti ADAM8 antibody, i.e. MAB 1031, 
Gd-chelate, and actively loaded with DOX. To actively target (ADAM8 antibody), image (Gd-
chelate) and treat (DOX) the triple-negative breast cancer cells.  
The main aspects that were achieved in this project are:  
 Development of thermosensitive liposomes. Characterization of the thermosensitive 
capabilities using DLS, DSC, AFM and TEM.  
 Active remote loading of DOX into thermosensitive liposomes using ammonium sulfate 
gradient. Characterization of the durg loading efficiency and drug release profile.  
 Development of image guide drug delivery system by incorporation of Gd-chelate for 
imaging under UHF-MRI. Characterization of liposomes was achieved with DLS, AFM 
and TEM images provided an insight into the Gd-chelate deposition, the contrast of the                 
Gd-containing liposomes provided an insight into the use of the liposomes for imaging 
under UHF-MRI. Quantification of relaxation rate after heating of the liposomes 
provided a proof for the heat-responsive properties of liposomes, as well as cytotoxicity 
assay of the liposomes under different temperatures and time intervals  
 The conjugation of MAB 1031 antibody to the liposomes resulting in 
immunoliposomes. MAB 1031 conjugate-immnoliposomes target TNBC cells, that 
show overexpression of ADAM8 receptors on their cell membranes. The 
characterization of immunoliposomes using DLS, AFM and TEM. Additionally, the 
characterization of targetability and binding capabilities of immunoliposomes against 
TNBC cells.  
 Finally, the establishment of a combined nanocarrier that utilizes thermosensitive 
properties, image-guided drug delivery system, triggered release, and active targeting 
of specific receptors. 
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Figure 9: Graphical abstract of the use of nanoscale carrier 
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2. Materials and Methods 
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2.1. Material  
 
2.1.1. List of Materials  
 
Materials / Substances Source 
HEPES ≥ 99 % VWR International GmbH, Darmstadt, 
Germany 
0.2 μm PES syringe filters Whatman plc, Buckinghamshire, UK 
12-well plates; Nunclon Delta Nunc GmbH & Co. KG., Wiesbaden, 
Germany 
5 ml glass vials Schott AG Müllheim, Germany 
96-well plates NUNC, Thermo ScientificTM, Germany 
Atomic force microscope; Nanowizard® 1 JPK Instruments AG, Berlin, Germany 
Autoclave, Tuttnauer 3850 ELC Tuttnauer GmbH, Linden, Germany 
Ammonium sulfate Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Cell culture lysis reagent Promega GmbH, Mannheim, Germany 
chamber slides NUNC, Lab-Tek, Germany 
Chloroform Merck, Darmstadt, Germany 
Chlorpromazine Alfa Aesar GmbH & Co. KG., Karlsruhe, 
Germany 
CO2 incubator, HeraCell Heraus GmbH & Co. KG., Hanau, 
Germany 
Coagulation analyzer; Coatron M1 Teco GmbH, Neufahrn, Germany 
Copper grids Plano, Wetzlar, Germany 
DAPI Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Dialysis bag (MWCO = 6,000-8,000) Repling europ B.V, Brend Netherland 
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Disposable folded capillary cell; DTS1060 Malvern Instruments Ltd, Malvern, UK 
DMEM Biochrom GmbH, Berlin, Germany 
DMSO; ≥ 99 % Acros Organics B.V.B.A., Geel, Belgium 
DODA-DTPA PD. Dr. U. Rothe, MLU Halle, Germany 
Doxorubicin hydrochloride OAO ONOPB, Moscow, Russia 
DPPC Lipoid GmbH, Ludwigshafen, Germany 
DSC-7  Perkin Elmer, Rodgau, Germany 
DSPC Lipoid GmbH, Ludwigshafen, Germany 
DSPE-mPEG-2000 Lipoid GmbH, Ludwigshafen, Germany 
DSPE-PEG2000-Cyanur Avanti Polar Lipids Inc., Alabaster, USA 
Egg puncher Schuett biotech, Göttingen, Germany 
Eppendorf pipette  Eppendorf, Hamburg, Deutschland 
Ethanol Carl Roth GmbH + Co. KG., Karlsruhe, 
Germany 
Ethidium bromide Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Extruder; Avanti Mini Avanti Polar Lipids Inc., Alabaster, USA 
Fertilized eggs Mastkükenbrüterei Bormann, Rheda-
Wiedenbrück, Germany 
Fetal calf serum PAA, Cölbe, Germany 
Filipin III Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Fluorescence microscope CKX-53 Olympus, USA 
FluorSave™ Calbiochem, San Diego, USA 
Formaldehyde Alfa Aesar GmbH & Co. KG., Karlsruhe, 
Germany 
Gadolinium trichloride Sigma-Aldrich, Taufkirchen, Germany 
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Glass slides Zeiss Axiovert 100M, Carl Zeiss 
Microscopy, Jena, Germany 
HEPES  Carl Roth, Karlsruhe, Deutschland 
Infrared thermometer Scantemp 385 Carl Roth, Karlsruhe, Germany 
Isotonic NaCl B.Braun Melsungen AG, Melsungen, 
Germany 
Laminar flow hood; Labgard Class II NuAire Inc., Plymouth, USA 
Confocal laser scanning microscope Carl Zeiss Microscopy GmbH, Jena, 
Germany 
Luminometer; FLUOstar® Optima BMG Labtech, Ortenberg, Germany 
Lyso Tracker® red DND-99 Thermo Fischer Scientific, Dreieich, 
Germany 
MAB-1031 R&D Systems, Inc.,Minneapolis, USA 
Magnetic stirrer; MCS 66 CAT Scientific, Paso Robles, USA 
MDA-MB-231-ctrl cell ATCC (American Type Cell Culture, 
Manassas, USA 
MDA-MB-231-rna cell Prof Jörg. W. Bartsch. Department of 
Neurosurgery, Philipps University Marburg, 
University Hospital Marburg, Germany 
Methanol Merck, Darmstadt, Germany 
MicroCal VP-DSC Microcal, Northampton, MA, USA 
Microscopy slides Gerhard Menzel B.V. & Co. KG., 
Braunschweig, Germany 
MilliQ® water Millipore Corporation, Billerica, USA 
Mounting medium; FluorSave™ Calbiochem Corporation, San Diego, 
USA 
MTT reagent Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
NBD-PE  Avanti Polar Lipids Inc., Alabaster, USA 
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Ø 15 mm over slips Gerhard Menzel B.V. & Co. KG., 
Braunschweig, Germany 
Opaque 96-well plates Brand GmbH + Co. KG., Wertheim, 
Germany 
Peristaltic pump PD5001, Heidolph Instruments, Schwabach, 
Germany 
Petri dishes 
 
Sarstedt AG & Co., Nümbrecht, Germany 
Polycarbonate membranes Whatman plc, Buckinghamshire, UK 
Rotary evaporator; Laborota 4000 Heidolph Instruments GmbH & Co. KG., 
Schwabach, Germany 
Sephadex-G50 Pharmacie Fine Chemicals, Sweden 
Sepharose CL-4B Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Shaker KS4000 IC IKA Werke, Staufen, Germany 
TEClot aPTT-S Kit Teco GmbH, Neufahrn, Germany 
Transmission electron microscope; JEM-
3010 
JEOL Ltd., Tokyo, Japan 
Triton™ X-100 Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Trypsin-EDTA, (0.5 %) in DPBS (10x) Capricorn Scientific GmbH Ebsdorfergrund, 
Germany 
UHF-MRI (7T), Clinscan  Bruker BioSpin GmbH, Rheinstetten, 
Germany 
Ultrasound bath sonicator (Bandelin Sonorex RK 100H, Bandelin 
Electronic, Berlin, Germany 
Uranyl acetate Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
UV mini 1240 Shimadzu, Suzhou, China 
Vacuum pump; SC 920 KNF Neuberger GmbH, Freiburg, Germany 
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Water bath Bruker Biospin MRI GmbH, Ettlingen, 
Germany 
Zetasizer Nano ZS Malvern Instruments Ltd, Malvern, UK 
 
 
2.1.2. DPPC 
 
DPPC is a phospholipid, contains a head group (polar phosphate) and a nonpolar fatty acid 
chain. DPPC is an amphipathic lipid with a molecular weight of 734.039 g/mol. It is the most 
reasonable lipid that is used in thermosensitive liposomes since it is has a phase transition 
temperature of Tm = 41 °C. DPPC has the ability to arrange itself in polar and non-polar 
interactions to form spherical vesicles [118]. Usually, it is used with cholesterol which plays a 
role as a membrane stabilizer. The DPPC used for this work had a purity of ≥ 99 %. It was 
dissolved in 2:1 (v/v) chloroform: methanol mixture at a concentration of 10 mg/ml and stored 
in glass vials at -20 °C until use.  
 
 
 
 
DPPC 
 
2.1.3. DSPC 
 
DSPC is a phosphatidylcholine with alkyl chains comprising 18 carbons [119]. DSPC is an 
amphipathic lipid with a molecular weight of 790.145 g/mol and it is used in several liposomal 
formulations. It is as well used in thermosensitive liposomes, as the unwanted drug leakage at 
body temperature can be reduced by mixing DPPC with small amounts of DSPC awing that its 
phase transition temperature is Tm =55 °C [53,120,121]. The DSPC used for this work had a 
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purity of ≥ 99 %. It was dissolved in 2:1 (v/v) chloroform: methanol mixture at a concentration 
of 10 mg/ml and stored in glass vials at -20 °C until use.  
 
 
 
DSPC 
 
 
2.1.4. DSPE-mPEG-2000 
 
DSPE-mPEG2000 (1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy 
(polyethyleneglycol)-2000] ammonium salt) is a modified lipid that is normally added to 
phospholipids vesicles to provide a steric coating on the surface of the vesicles membrane 
making them stealthier and provide prolonged circulation plasma half-life of the nanocarrier. 
Its molecular weight is 2805.497 g/mol. It is used for this work with a purity of ≥ 99 %. It was 
dissolved in 2:1 (v/v) chloroform: methanol mixture at a concentration of 10 mg/ml and stored 
in glass vials at -20 °C until use.  
 
 
 
DSPE-mPEG-2000 
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2.1.5. Cholesterol  
 
Cholesterol is a hydrophobic steroid molecule that exists in the serum, it is a lipophilic molecule 
with a single polar hydroxyl group. Its molecular weight is 386.65 g/mol. Cholesterol is 
incorporated into the liposomal lipid bilayer to stabilize the membrane. It prevents vesicle 
aggregation [122], it does as well affect the phase transition temperature of the liposomes [123]. 
Cholesterol was dissolved in 2:1 (v/v) chloroform: methanol mixture at a concentration of 10 
mg/ml and stored in glass vials at -20 °C. 
 
 
 
 
Cholesterol 
 
 
2.1.6. NBD-PE 
 
NBD-PE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3benzoxadiazol-
4-yl) (ammonium salt) is a phospholipid with fluorescent labelled headgroup. L-α-
Phosphatidylethanolamine (PE) is the most copious phospholipid in bacteria and the second 
most copious in animals, plants, and yeast [124]. It is mostly used for fluorescence-labeled 
experiments. NBD-PE was dissolved in 2:1 (v/v) chloroform: methanol mixture at a 
concentration of 1 mg/ml and stored in glass vials at -20 °C. 
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NBD-PE 
 
 
2.1.7. DSPE-PEG2000-cyanur 
 
Cyanuric PEG-PE is an end group functionalized PEG-lipid conjugate used for attachment of 
peptides, antibodies, etc., under mild basic conditions. Cyanuric chloride is one heterocyclic, 
nitrogen-containing compound with three chlorine atoms, which group links the antibodies to 
the PEG terminus via a nucleophilic substitution at a basic pH (8.8) with either primary and 
secondary amine. A big advantage of using cyanuric PEG-PE is that the proteins can be coupled 
to this membrane anchor without the need for any previous derivatization [75].  
DSPE-PEG2000-cyanur was dissolved in 2:1 (v/v) chloroform: methanol mixture at a 
concentration of 1 mg/ml and stored in glass vials at -20 °C. 
 
 
 
DSPE-PEG2000-cyanur 
 
 
2.1.8. Chelator                      
 
2-[2-[2-[bis(carboxymethyl)amino]ethyl-[2-(dioctadecylamino)-2-oxoethyl]amino]ethyl-
(carboxymethyl)amino] acetic acid is a chelator that has diethylenetriaminepentaacetic acid 
(DTPA) backbone that is modified with the addition of dioctadecylamine (DODA).  
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DTPA is a diethylenetriamine backbone with five carboxymethyl groups, while DODA is 
secondary amine, which is a fatty amine derivative. One of the OH groups in DTPA is 
substituted with a secondary amine. DODA has been utilized in the formulation of liposomes, 
polymeric conjugates, and others [125]. 
In the complex of Gd3+ and DODA-DTPA the Gd3+ ion is 9 coordinate, surrounded by the 3 
nitrogen atoms and 5 oxygen atoms from the carboxylate groups (Figure 10) [126]. Notably, 
the 9th coordination site is occupied by a water molecule (H2O). Thus allowing the water 
molecule to rapidly exchange other water molecules in the immediate vicinity of the Gd 
complex [127]. Hence, allowing the protonation and relaxation of water molecules under MRI 
[128].  
 
 
 
 
Figure 10: Chelating of gadolinium by DODA-DTPA. 
 
2.2. Methods  
 
2.2.1. Preparation of liposomes 
 
Three different thermosensitive liposomal formulations were prepared. Appropriate mole 
fraction combination of different lipids (DPPC:DSPC:Chol:DSPE-mPEG2000) at molar ratios 
of 89:8.8:2:0.2 was used to prepare thermosensitive liposomes (LipTS). The magnetic 
contrasting agent gadolinium trichloride was incorporated into thermosensitive liposomes of 
the previously mentioned composition adding a chelator at molar ratios of 85:7.8:2:0.2:5 
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(DPPC:DSPC:Chol:DSPE-mPEG2000:Chelator) leading to LipTS-GD. Magnetic 
thermosensitive liposomes with cyanur (LipTS-GD-CY) were prepared based on 
DPPC:DSPC:Chol:DSPE-PEG2000-cyanur:Chelator at 80:8:5:2:5 molar ratio. For 
fluorescence detection, 1 mol % NBD-PE was incorporated into the liposomal preparations. All 
liposomes were prepared using thin-film hydration techniques as previously reported [129]. 
Briefly, the appropriate amounts of lipids or lipids and chelator were diluted in a mixture of              
chloroform : methanol (2:1 v/v). The organic solvent was subsequently evaporated under an 
escalating vacuum using the rotary evaporator Heidolph Laborota 4000 efficient (Heidolph 
Instruments, Schwabach, Germany). The temperature was held slightly above the phase 
transition temperature of the dominant lipid in the mixture at 56 ºC until a thin film was 
deposited. Crude multi-lamellar vesicles (MLV) were formed after the addition of 250 mM 
ammonium sulfate solution, including 0.5 mM gadolinium in case of LipTS-GD and LipTS-GD-CY 
[130]. The colloidal solution was sonicated at 56 °C for 20 min using ultrasound bath sonicator 
(Bandelin Sonorex RK 100H, Bandelin Electronic, Berlin, Germany) at maximal energy. The 
sonicated liposomes were subjected to extrusion using mini-extruder (Avanti Polar Lipids, 
Alabaster, USA) equipped with polycarbonate membranes (200 nm and 100 nm) for 21 times 
at 56 °C. The small unilamellar vesicles (SUV) were then used to encapsulate Doxorubicin 
(DOX). SUV liposomes were 20-fold diluted in HEPES buffer at pH 8.4 and the loading of 
DOX has achieved at DOX: total lipids molar ratio of 0.2:1 using ammonium sulfate gradient 
technology [131,132]. The final theoretical load of DOX was [C] DOX = 1 mg/ml in  
[C]lipids = 5 mg/ml lipids. Purification of free DOX and Gd-chelate from the prepared liposomes 
was done using size exclusion chromatography (SEC) utilizing Sephadex-G50 column [133]. 
Prepared liposomes were kept in dark at +4 °C until use. Liposomes were filtered through a  
0.2 µm syringe filter before using. 
 
 
2.2.1.1. Conjugation of antibody to the liposomes 
 
Immuno magnetic thermosensitive liposomes with cyanur (LipTS-GD-CY-MAB) were prepared by 
coupling MAB 1031 antibody to the surface of LipTS-GD-CY, an initial phospholipid / MAB 1031 
molar ratio of 1000:1 was chosen, as previously optimized [134]. Liposomes containing DSPE-
PEG2000-cyanur were prepared in HEPES buffer at pH 8.4. The indicated amount of MAB 
1031 was dissolved in borate buffer to adjust pH at 8.8 and incubated with the grafted liposomes 
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at DSPE-PEG2000-cyanur : MAB 1031 molar ratio of 50:1 at room temperature for 20 h, then 
for 4 h under shaking at 100 rpm. The primary chlorine atom of cyanuric chloride is very 
reactive, which can react after minutes with the antibody. The second chlorine atom may take 
up to 24 hours at room temperature to form a stable bond. Whereas, the third chlorine group 
needs drastic reaction conditions to obtain any form of binding. The coupling step with an 
antibody requires the presence of proton acceptor (Figure 11). The MAB 1031 surface-modified 
liposomes were separated from unbound MAB 1031 bypassing the liposomes over Sepharose 
CL-4B and eluting with PBS pH 7.4 [75].  
 
 
Figure 11: Binding of MAB-1031 antibody to DSPE-PEG2000-cyanur in the lipid bilayer of 
the liposome. 
 
 
Antibodies in the PEGylated or non-PEGylated liposomes can either conjugate directly to the 
liposomes shell or by the help provided by the PEGylation (Figure 12). One possibility to 
achieve conjugation of the antibody is the use of an anchor that paves the conjugation to the 
antibody. Here, cyanuric chloride is used and could obtain the conjugation via nucleophilic 
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substitution at pH 8.8. Moreover, the PEG facilitated conjugation is advantageous for anchoring 
the antibody to interact with different cellular receptors. 
Moreover, by the use of DOX loaded immunoliposomes one can achieve an active targeting to 
the TNBC cells, thus offering the desired therapeutic effects of delivering DOX selectively to 
the tumor site with the required cumulative dose as well as minimizing its dose-related toxicity.  
 
 
Figure 12: Schematic representation for the possibility of antibodies binding to the liposome. 
Directly on the surface of non-PEGylated liposomes (A), Directly on the surface of PEGylated 
liposomes (B) and antibody bound to the end of the PEG chains, by the use of PEGylated lipids 
with anchor molecule, e.g. DSPE-PEG2000-cyanuric (C). 
 
 
2.2.2. Dynamic light scattering  
 
Hydrodynamic diameters of the prepared liposomes were analyzed by Dynamic Light Scattering 
(DLS) (Zetasizer Nano ZS, Malvern Panalytical, Herrenberg, Germany) in a clear disposable 
folded capillary cell (DTS1060; Malvern Instruments). DLS is equipped with a 10 mW HeNe  
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laser at a wavelength of 633 nm at 25 °C. The scattered light was detected at an angle of 173º. 
The obtained results were presented as an average value ± standard deviation of three 
independent preparations with three replicate measurements of each preparation for at least 10 
runs. The refractive index (1.33) and viscosity (0.88 mPa.s) of water at 25 ºC were considered 
for analysis of the data [135].  
 
 
2.2.3. Laser Doppler velocimetry 
 
Zeta potential of the liposomes was measured by Doppler velocimetry (LDV) using the 
Zetasizer Nano ZS in a clear disposable folded capillary cell (DTS1060; Malvern Instruments). 
The scattered light is collected at an angle of 17º. Prior to the measurement, liposomes were 
diluted with Milli-Q water 1:100. Laser attenuation and position were automatically adjusted 
by the instrument depending upon the sample. The obtained results were presented as an 
average value ± standard deviation of three independent with three replicate measurements of 
each preparation for at least 10 runs.  
 
 
2.2.4. DOX entrapment efficiency  
 
Size exclusion chromatography (SEC) is utilized to separate the free DOX from the DOX-
encapsulated liposomes. Prior to adding DOX-liposomes, the Sephadex-G50 column was 
saturated with empty liposomes of the measured formulation to prevent any remarkable loss of 
lipid material. The concentration of DOX in the liposomes obtained after SEC was measured 
using UV/Vis spectrophotometry (UV mini 1240, Shimadzu, Suzhou, China). The amount of 
encapsulated DOX was calculated according to equation (4) using a calibration curve of DOX 
in HEPES buffer [136]. 
 
𝐸𝐸 % =  
𝐷𝑂𝑋 𝑎𝑚𝑜𝑢𝑛𝑡 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑡𝑒𝑑
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓𝐷𝑂𝑋 
 𝑥 100%         Equation 4 
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2.2.5. Atomic force microscopy 
 
The morphology and surface structure of the liposome were visualized using atomic force 
microscope NanoWizard® 3 NanoScience provided by JPK Instruments (Berlin, Germany). 
AFM was in a soundproofed chamber during the measurements. The measurements were 
achieved at room temperature.  
Twenty microliters of diluted liposomes in Milli-Q water (1:1000) were pipetted onto a 
microscope slide. Liposomes were left for 5 min to sediment and the excess liquid was aspirated 
leaving a thin film of aligned vesicles on the microscope slide. Commercial 1-lever tips (NSC 
14 Al/BS) on a cantilever with a length of 125 µm and a resonance frequency of 140 Hz and a 
force constant of 5 N/m were applied. All acquisitions were performed in intermittent contact 
mode. Scan speed was adjusted between 0.5 and 1.5 Hz. Raw images were processed using 
JPKSPM software [137]. 
 
 
2.2.6. Transmission electronic microscopy 
 
Surface structure and morphology of the prepared liposomes were investigated using the 
transmission electron microscope (TEM) JEM-3010 (JEOL, Japan) with a retractable high-
resolution slow-scan CCD-Camera (Gatan MegaScan 794). The liposomes were heated at        37 
°C or UHF- MRI for one hour before they were subjected to TEM visualization at 80kV. Liposomes 
were diluted 1:10 with 10 mM HEPES buffer (pH 7.4) before staining with uranyl acetate (2 %) for 
30 minutes. Liposomes were pipetted onto 300 mesh formvar coated S160-3 copper grids (Plano 
GmbH Wetzlar, Germany). Equal parts of the sample and uranyl acetate were mixed together 
and the grid was incubated for 5 min in this solution. The mixture was examined at an 
accelerating voltage of 300 kV and 110 µA emission current with current densities between 50-
60 pA/cm2. 
 
 
2.2.7. Differential scanning calorimetry 
  
Differential scanning calorimetry (DSC) measures the heat capacity depending on the 
temperature. DSC measurements were performed to determine the phase transition transforming 
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from the liquid condensed to liquid expanded phase of phospholipid mixtures of the prepared 
liposomes.  
The DSC measurements for the LipTS-GD were performed on MicroCal VP-DSC. MicrocalInc., 
Northampton, MA, USA, scanned temperature range was 20 and 60 °C, the heating rate was 
60 °C per hour. The reference cells were filled with buffer, and the buffer-buffer baseline was 
deducted from the thermograms of the liposomes. MicroCal Origin 8.0 software was utilized 
to analyze the DSC scans, the peak maximum was set as the transition temperature (Tm) [138].  
The DSC measurements for LipTS-GD-CY-MAB were performed on DSC-7 (Perkin Elmer, 
Rodgau, Germany). The scanned temperature range was between 35 to 50 °C, the heating rate 
was 6 °C per hour. The reference cells were filled with HEPES buffer, and the buffer-buffer 
baseline was subtracted from the thermograms of the liposomes. DSC scans were analyzed 
using Pyris software, peak maximum was set as the transition temperature (Tm).  
 
 
2.2.8. Drug release 
 
To determine DOX release from the nanocarrier system, cumulative release of DOX from the 
LipTS-GD / LipTS-GD-CY-MAB were performed at 37, 38, 39 and 40 °C at different time intervals (up 
to 60 min). 2 ml of DOX-LipTS-GD / DOX-LipTS-GD CY-MAB were suspended in 1 ml HEPES      
(pH = 7.4), transferred into a dialysis bag (MWCO = 6,000-8,000) and incubated in 20 ml of 
HEPES pre-heated to the aforementioned temperatures with stirring speed of 100 rpm. 1 ml 
from the outer HEPES buffer was collected at selected time points and replaced with 1 ml of 
fresh HEPES. To determine the amount of DOX released at different time points, collected 
samples were analyzed by UV/Vis spectrophotometry (UV mini 1240, Shimadzu, Suzhou, 
China). The amount of DOX released was calculated according to equation 5 using a calibration 
curve of DOX in HEPES buffer. 
 
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝐷𝑂𝑋 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 % =  
𝐷𝑂𝑋 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓𝐷𝑂𝑋 
 𝑥 100%               Equation 5 
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2.2.9. Ultra high field magnetic resonance imaging 
 
The ultra high field magnetic resonance imaging (UHF-MRI) (Figure 13) measurements were 
performed on a 7 Tesla UHF-MRI (Bruker BioSpin GmbH, Rheinstetten, Germany) with a 
birdcage coil by applying a diffusion sequence for all images and measurements. The 
quantification of the T1 times was performed with an inversion recovery sequence (TR: 7000 
ms, TE: 7.9 ms) and different TI (500, 1000, 1500, 2000, 25000) ms. Syngo's Dynamic Analysis 
application created T1 maps before and after warming by a water bath (Bruker Biospin MRI 
GmbH, Circulating Thermostat C-10-P5/U230/50-60) from the acquired images. The change 
in temperature after UHF-MRI treatment was monitored by infrared thermometer (IR) 
Scantemp 385 (Carl Roth, Karlsruhe, Germany).  
 
 
Figure 13: Ultra high field-magnetic resonance imaging (UHF-MRI); 7 Tesla. 
(https://www.uni-marburg.de/de/fb20/forschung/corefacilities/7t-kleintier-mrt) 
 
 
2.2.10. Cell conditions  
 
Two cell lines were utilized in this project. Both cells are Triple-negative breast cancer cells i) 
MDA-MB-231-ctrl with high endogenous ADAM8 expression and ii) MDA-MB-231-rna with 
ADAM8 knockdown. MDA-MB-231-ctrl cells were obtained from ATCC (American Type 
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Cell Culture, Manassas, USA). MDA-MB-231-rna (ADAM8 knockdown) cells were obtained 
from Prof. Dr. Jörg-Walter Bartsch (Neurosurgery, University Hospital Marburg) [139]. Both 
cells were cultivated in Dulbecco's Modified Eagle Medium (DMEM) (Biochrom, Berlin, 
Germany) at 37 ºC and 7 % CO2 under humid conditions. The media were boosted with 10 % 
fetal calf serum (PAA, Cölbe, Germany). 
 
 
2.2.11. Cytotoxicity studies upon hyperthermia 
 
MDA-MB-231-ctrl cells were passaged when they reach about 95 % confluency. The cells are 
adherent cells, from these adherent cells the old medium was removed carefully, then 1ml 
Trypsin/EDTA was added, followed by incubation for 5 min. Trypsin was neutralized after 
adding 10 ml medium. The suspended cells were filled in a 15 ml sterile tube and centrifuged 
at 9000 g for 5 min. The medium was aspirated and replaced with 1 ml fresh medium. Cells 
with the 1 ml fresh medium were transferred to a sterile petri dish with 9 ml fresh medium. At 
the time of passage, MDA-MB-231-ctrl cells were seeded into 96-well plates (NUNC, Thermo 
ScientificTM, Germany) at a cell density of 10,000 cells/cm2. 
 
 
2.2.11.1. Thermal therapy in the incubator  
 
MDA-MB-231-ctrl cells were seeded into 96-well plates (NUNC, Thermo ScientificTM, 
Dreieich, Germany) at a cell density of 10,000 cells/well and kept at 37 °C for 24 h. After 24 h, 
the cells were incubated with DOX-liposomes for 3 or 3.5 hours at 37 °C, followed by thermal 
treatment either at 38 or 39 or 40 ºC. Different thermal therapy times of 30 and 60 min for each 
temperature were applied in the case of LipTS-GD.  
In the case of LipTS-GD-CY and LipTS-GD-CY-MAB, cells were incubated with DOX-liposomes (DOX 
concentration = 100 µg/ml) for 3 hours at 37 °C, followed by thermal treatment either at 38 or 
39 or 40 ºC for 60 min. The medium was replaced with fresh medium and cells were further 
incubated for 24 h. Control untreated cells were similarly incubated at the same temperatures 
and incubation times.  
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2.2.11.2. Thermal therapy under magnetic field 
 
MDA-MB-231-ctrl cells were seeded in 2 well-Chamber slides at a cellular density of  
20,000 cells/well. LipTS-GD liposomes were incubated with the cells for 3 or 3.5 hours at 37 °C 
followed by cellular exposure to UHF-MRI field for 60 or 30 minutes, respectively.  
In the case of LipTS-GD-CY and LipTS-GD-CY-MAB, liposomes were incubated for 3 hours with DOX 
final concentration of 100 µg/ml at 37 °C followed by cellular exposure to UHF-MRI field for 
60 min [56,140]. The cells were further incubated for 24 hours. Control untreated cells were 
similarly incubated at the same temperatures, incubation times and UHF-MRI conditions. 
To simulate physiological temperature and prevent hypothermia due to room temperature 
during UHF-MRI exposure, chamber slides were kept on temperature pads, that were contacted 
with heated water tubes to keep 37 °C as an initial point (Figure 14). 
 
Figure 14: Schematic representation of an adjusted water bath system to keep 37 °C as an 
initial temperature inside UHF-MRI to prevent hypothermia. 
 
2.2.11.3.  MTT cell viability assay 
 
Cytotoxicity after thermal therapy was determined by measurement of cell viability based on 
the cellular redox potential as previously reported [141]. Briefly, the medium was aspirated and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent was 
subsequently added. Cells were further incubated for 4 h in the dark. Actively respiring cells 
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convert the water-soluble MTT to an insoluble purple formazan. The formazan was then 
solubilized in DMSO and its concentration was determined at 570 nm using a plate reader 
(FLUOstar, BMG, Germany). Untreated cells were used as a control representing 100 % 
viability [142,143]. Results were expressed as mean ± standard deviation (SD). 
MDA-MB-231-rna cells were non-stable against the temperature, that’s why no viability assay 
was determined on MDA-MB-231-rna cells. 
 
 
2.2.12. Cellular uptake evaluation 
  
At the time of passage, MDA-MB-231-ctrl cells were grown at a cell density of 1x105 cells/cm2 
on 18 x 18 mm sterile cover glasses at 37 °C for 18 h. The cells were incubated with LipTS-GD 
liposomes for 3 h at 37 °C followed by thermal therapy at 40 °C or cellular exposure to UHF-
MRI field for 60 min. In another set of experiments, cells were incubated with  
LipTS-GD liposomes for 4 h at 37 °C without exposure to UHF-MRI field. The medium was then 
aspirated and cells were washed with Ca2+ and Mg2+ containing PBS buffer. The cells were 
fixed with 4 % paraformaldehyde for 10 min at room temperature. The cell nuclei were stained 
by addition of 4',6-diamidino-2-phenylindole (DAPI) at 3.63 mM for 2 min [144]. The cells 
were washed again with the buffer, and the cover glass was transferred onto glass slides for 
imaging with a confocal laser scanning microscope (Carl Zeiss Microscopy GmbH, Jena, 
Germany). 
 
 
2.2.13. Pathway studies 
 
MDA-MB-231-ctrl cells were seeded into 96-well plates (NUNC, Thermo ScientificTM, 
Dreieich, Germany) at a cell density of 10,000 cells/well and kept at 37 °C for 24 h. Cells were 
incubated with Filipin III or Chlorpromazine (10 µg/ml) for 1 h, then treated with  
DOX-LipTS-GD-CY or DOX-LipTS-GD-CY-MAB for 3 h at 37 °C followed by UHF-MRI for 1 h using 
the same protocol explained earlier (2.2.11.2). The medium was replaced by fresh medium and 
the cells were incubated for 24 h, MTT assay was used to determine the cell viability. As a 
blank, cells were treated with DOX-LipTS-GD or DOX-LipTS-GD-MAB at 37 °C for 4 h without 
inhibition. 
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2.2.14. Mechanism of endosomal escape by fluorescence microscopy 
 
To evaluate the endosomal escape of the nanocarrier system into the cells. MDA-MB-231 cells 
(ctrl / rna) were seeded at the seeding density of 1 x 105 cells per well in a 12-well cell culture 
plate on glass coverslips. After overnight incubation, the medium was replaced with fresh 
medium and incubated with the NBD labeled liposomes (LipTS-GD-CY or LipTS-GD–CY-MAB). After 
4 h of cell incubation, 100 nM of Lyso Tracker® red DND-99 was added to the cells and further 
incubated for 30 min at 37 °C under humid conditions. Thereafter, DAPI staining was 
performed as described earlier (2.2.12). The coverslips were placed on a clear glass slide 
containing a drop of mounting medium (FluorSave™, Calbiochem, San Diego, USA) before 
being analyzed under a fluorescence microscope (CKX-53 Olympus, USA). Equipped with 
fluorescence detection filters for LysoTracker® red (ex. 577 nm - em.590 nm) and DAPI (ex.385 
nm - em.470 nm). 
 
 
2.2.15. In vitro evaluation of ADAM8 targeting by immunoliposomes 
 
To evaluate the targeting effect of immuno/non-immuno liposomes, MDA-MB-231 cells       
(ctrl / rna) cells were used. We used a monoclonal mouse antibody (MAB 1031) (R & D 
Systems, Minneapolis, MN, USA) that detects the aa 201 - 497 epitope of the human ADAM8 
ectodomain, i.e. the section of the protein-membrane that protrudes away from the cell wall into 
the extracellular space. 
 
 
2.2.15.1. Washing method 
 
MDA-MB-231 (ctrl / rna) were seeded at a density of 1x105 cells/cm2. After overnight 
incubation cells were incubated for 2 h with NBD liposomes at +4 °C to avoid any endocytotic 
events [75]. Afterward, the medium containing liposomes was aspirated and cells were washed 
with activity buffer (20 mM Tris-Cl pH 8, 10 mM CaCl2, 1 μM ZnCl2, 0.0006 % Brij®) for  
5 times, then the activity buffer was aspirated and cells were washed with PBS buffer containing 
Ca2+ and Mg2+. The cells were fixed with 4 % paraformaldehyde for 10 min, and DAPI staining 
was performed as described earlier (2.2.12) following by washing with PBS buffer.  
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The cover glass was transferred onto glass slides for imaging with a confocal laser scanning 
microscope (Carl Zeiss Microscopy, GmbH, Jena, Germany) or fluorescence microscope  
(CKX-53 Olympus, USA) using GFP filters (ex.505 nm - and em.530 nm). LipTS-GD-CY-MAB 
binding ability to MD-MB-231-ctrl cells was compared to LipTS-GD-CY. 
Additionally, UHF-MRI images were acquired after washing with both LipTS-GD-CY and       
LipTS-GD-CY-MAB, to confirm UHF-MRI activity of the liposomes after cell binding and mean 
gray value was measured. 
 
 
2.2.15.2. Circulation method 
 
To portray in vivo like conditions, a model circulation system was established (Figure 15), using 
a pulsed peristaltic pump (PD5001, Heidolph Instruments, Schwabach, Germany). Sterilized 
silicone tubes with a diameter of 4.0 mm were used (similar to the size of a middle-sized vein) 
and their ends were attached to a well-designed chamber that can accommodate three cover 
glasses at the same time. Briefly, MDA-MB-231 (ctrl / rna) cells were seeded at the seeding 
density of 1 x 105 cells per well in a 12-well cell culture plate containing glass coverslips. After 
overnight incubation, coverslips were placed in the chamber and NBD labeled liposomes 
(LipTS-GD-CY or LipTS-GD-CY-MAB) were allowed to circulate for 30 min. The velocity of circulation 
was set at 2 cm/s to avoid the risk of washing off the cells from the coverslips. The binding 
efficiency of NBD labeled liposomes with the cell membrane was analyzed using a fluorescence 
microscope (CKX-53 Olympus, USA) using GFP filters (ex.505 nm - and em.530 nm) and for 
the quantitative determination the coverslips were dipped in 1 % Triton-X-100® and 
fluorescence was measured using a microplate reader FluorStar Optima (BMG Labtech, 
Ortenberg, Germany) at excitation and emission wavelength of 408 nm and 640 nm, 
respectively.  
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Figure 15: Schematic representation of the binding circulation model. 
 
2.2.16. Hemocompatibility studies 
 
2.2.16.1. Activated partial thromboplastin time 
 
Activated partial thromboplastin time (aPTT) was used to determine the effect of the prepared 
liposomes on the coagulation time. Fresh whole blood samples were taken into citrate tubes. In 
order to separate the plasma fraction, the blood samples were subjected to centrifugation at 
1500 g for 10 min. Activated partial thromboplastin time (aPTT) was determined using a 
Coatron M1 coagulation analyzer (Teco, Neufahrn, Germany) using aPTT-S Kit (TEClot) 
according to the manufacturer’s instructions as previously mentioned with some modifications 
[143]. Briefly, 25 µL of plasma was mixed with 25 µL of the sample preparation. 50 μL of 
aPTT reagent was mixed with the sample to activate coagulation factors followed by the 
addition of 50 µl previously warmed calcium chloride solution (0.025 M). Coagulation was 
confirmed spectrophotometrically and the time was recorded in seconds. 
 
 
2.2.16.2. Ex vivo Hemolysis Assay  
 
Erythrocytes isolated from fresh human blood were used to determine the hemolytic potential 
of the prepared liposomes on blood [145]. Freshly isolated human erythrocytes were obtained 
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as previously described [143]. Briefly, fresh whole blood was withdrawn into EDTA containing 
tubes followed by centrifugation at 1500 g for 10 min. The obtained red blood cell pellet was 
subjected to three washing steps and diluted to 1:50 with NaCl. The diluted mixture of 
erythrocytes was incubated with various sample preparations for 1 h at 37 ºC in V-bottom 
microtiter plates in an orbital shaker KS4000 IC (IKA Werke, Staufen, Germany). The plates 
were then centrifuged and the collected supernatants were measured at 540 nm using FLUOstar 
Optima (BMG Labtech, Ortenberg, Germany) microplate reader. Parallel measurements of PBS 
buffer (pH 7.4) and 1 % Triton X-100® were used as controls and the absorbance values of 
Triton X-100® were considered as 100 % hemolysis. 
 
 
2.2.17. Chorioallantoic membrane model  
 
Fertilized eggs were obtained from Mastkükenbrüterei Bormann (Rheda-Wiedenbrück, 
Germany). The eggs were disinfected using 70 % ethanol and incubated in an egg hatching 
incubator at 37 °C and 65 % relative humidity. The incubator is equipped with an automatic 
rotor every 6 h to prevent the attachment of the developing embryo at the eggshell. The intact 
chorioallantoic membrane model (CAM) was prepared as reported elsewhere [146,147]. 
Briefly, on day 4 of embryo development (EDD 4), a hole of about 3 cm was made on the apical 
side of the egg using a pneumatic egg puncher (Schuett biotech, Göttingen, Germany) at a 
pressure of about 2-3 bars to expose the CAM surface. The exposed surface was then covered 
with a small petri dish and the egg was further incubated. On day 11 of embryo development 
(EDD 11) 15 eggs for each of: free DOX, DOX-LipTS-GD-CY or DOX-LipTS-GD-CY-MAB were 
injected intravenously in ovo under a stereomicroscope (Stemi 2000-C, Carl Zeiss, Göttingen, 
Germany). All instruments were disinfected with 70 % ethanol before use. After the treatment, 
the eggs were placed back into the incubator and the agility of embryo, the heartbeat and the 
state of vessel development were monitored and recorded daily until EDD 16. 
Additionally, LipTS-GD-CY-MAB was injected intravenously into the chick embryo vasculature and 
images were acquired using UHF-MRI (Bruker, Model Clinscan 70/30) to confirm the 
diagnostic potential of the prepared liposomes.  
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2.2.18. Statistical analysis 
 
All experiments were performed in triplicates and values are shown as mean ± standard 
deviation unless otherwise stated. A two-tailed Student´s t-test was performed to identify 
statistically significant differences. Probability values of p < 0.05 were considered significant. 
In all analyses, statistical differences are denoted as [*] p < 0.05, [**] p < 0.01, [***] p < 0.001. 
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3. Results and discussion 
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3.1. Hydrodynamic diameter and Zeta potential 
 
Dynamic light scattering was used to investigate the size of the prepared liposomes. LipTS 
obtained a size of 120.43 ± 1.91 nm. The Particle size increased upon the incorporation of          
Gd-chelate within LipTS-GD and LipTS-GD-CY lipid bilayer to 134.53 ± 17.45 nm and                 
126.90 ± 12.56 nm, respectively. The minor increase in size is ascribed to the size of Gd-chelate 
and its alignment within the lipid bilayer. The conjugation of MAB 1031 to LipTS-GD-CY to form 
LipTS-GD-CY-MAB resulted in an increase of the particle size to reach 167.98 ± 11.53 nm, which 
could be accounted to the size of MAB 1031 [148] or MAB-MAB dimeric formation. Further 
investigation of the polydispersity index (PDI) was carried out, a monomodal size distribution 
was observed in the case of LipTS, LipTS-GD and LipTS-GD-CY with a recorded PDI of 0.14, 0.16 
and 0.16, respectively (Table 1). The minor increase in the PDI after the incorporation of Gd-
chelate is ascribed to the protruding Gd-chelate moieties on the liposomal surface, where Gd-
chelate can be presented either as core-encapsulated, surface-conjugate or dually presented in 
the core and on the surface of the liposomes [149]. Multimodal size distribution was observed 
in the case of LipTS-GD-CY-MAB (PDI: 0.23), the multimodal distribution can be attributed to either 
MAB 10131 conjugation or to the formation of dimeric MAB-MAB.  
Laser Doppler velocimetry was used to measure Zeta potential of the formulated liposomes 
(Table 1), LipTS measured a Zeta potential of – 6.92 ± 2.64 mV, whereas the negative Zeta 
potential has increased in case of LipTS-GD to – 13.96 ± 5.09 mV. The increased in negative Zeta 
potential is an indication of the incorporation of the negatively charged Gd-chelate complex 
[GdDTPA]2-. These findings correspond with previously published results by Bartacek et al. 
[150]. In the case of LipTS-GD-CY, the Zeta potential measured – 50.66 ± 7.95 mV, A small variation 
to the charge was observed after the coupling of MAB antibody (LipTS-GD-CY-MAB), the Zeta 
potential was -43.93 ± 3.38 mV, which can be explained by the acquired charge of the antibody, 
these findings corresponded with previously published results [148,151].   
 
 
3.2. Encapsulation efficiency 
 
DOX was encapsulated into the liposomal payload using a remote loading method, the 
theoretical load of DOX was [C] DOX=1 mg/ml. Remote loading method is using a driving force 
for loading amphipathic weak bases such as DOX into liposomes, it was firstly reported by 
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Bahrenholz and his working group [45]. They have used an ammonium sulfate gradient, which 
facilitates the encapsulation of DOX into liposomes. DOX was reported to be exclusively 
encapsulated into the liposomal core by several authors [152,132]. 
 DOX encapsulation efficiency was 92.3 % in the case of LipTS. After the incorporation of Gd-
chelate the encapsulation efficiency decreased to 84.07 %. Pitchaimani et al. has reported that 
incorporating Gd-chelate raises concerns regarding drug encapsulation efficiency [153]. 
Nevertheless, our liposomes showed minimal retardation effect on DOX encapsulation 
efficiency into the liposomal core. In the case of LipTS-GD-CY the encapsulation efficiency was  
86.09 % (Table 1). After the addition of MAB antibody to the liposomes, no significant 
difference in the encapsulation efficiency was observed, where the encapsulation efficiency was 
86.01 %. It is noteworthy to mention that MAB was conjugated to the liposomes after the 
encapsulation of DOX into the liposomal payload, which explains the unaffected DOX 
encapsulation efficiency. 
 
 
3.3. Atomic force microscopy 
 
Atomic force microscopy was used to measure and visualize the morphological aspects of the 
prepared liposomes and help to better understand their surface characteristics. The average 
diameter of the liposomes measured on the AFM images corresponded well to the 
hydrodynamic diameter measured by dynamic light scattering. However, a slight increase was 
measured on the average diameter in AFM images (Table 1) that can be explained by the 
adhesion of the liposomes on the mica surface. AFM images showed mostly uniform round-
shaped vesicles and segregated patterns of the liposomes at 37 °C. The size of the liposomes 
was between 130 and 184 nm at 37 °C (Figure 16 A, B, D). An increase in liposomal size can 
be observed in the AFM images after the incorporation of Gd-chelate (Figure 16 B, D). The 
temperature stability of the liposomes was observed under AFM after hyperthermia application 
using UHF-MRI. The liposomes were burst and showed disrupted lipid film on the mica surface 
(Figure 16 C, E). For the assessment of the disruption of the liposomes, the amplitude model 
was utilized. The highest measured nm in all liposomes formulation was between 10 to 12 nm 
at 37 °C, whereas after UHF-MRI exposure in the presence of Gd-chelate it dropped down to 
be between 4 to 5 nm, which indicates the disruption of the liposomes and formation the flat 
lipid film. The amplitude model mainly gives an insight into the degree of surface roughness. 
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Surface roughness is defined as the calculated average of the height of the surface asperities, 
above a hypothetical, smooth plane, i.e. mica surface [154]. The decrease in surface roughness 
after hyperthermia corresponds with the change in the asperities and amplitude of the 
liposomes. The decrease in the amplitude suggests that liposomal integrity has been disrupted 
to a certain degree.  
Thus indicate that after hyperthermia liposomes have lost their structure, which is clearly shown 
by (Figure 16 C, F). These findings confirm the thermosensitive effects of the liposomes after 
UHF-MRI exposure. 
 
 
 
 
Table 1: Physiochemical properties of the liposomes. Particle size, polydispersity index (PDI), 
Zeta potential and encapsulation efficiency (EE) of LipTS, LipTS-GD, LipTS-GD-CY, and  
LipTS-GD-CY-MAB. As mean ± standard deviation of three independent measurements (n=3). 
 
 
Liposomes 
 
Particle size [nm] 
DLS±SD                          PDI 
Zeta potential 
± SD [mV] 
EE [%] AFM ± SD 
[nm] 
LipTS 120.43 ±  1.91         0.14 ± 0.02 -6.92 ± 2.64 92.3 ± 2.82 130.33 ± 21.55 
LipTS-GD 134.53 ± 17.45          0.16 ± 0.06 -13.96 ± 5.09 84.07 ± 2.90 154.67 ± 15.83 
LipTS-GD-CY 126.90 ± 12.56        0.16 ± 0.05 -50.66 ± 7.95 86.09 ± 3.20 138.66 ± 34.89 
LipTS-GD-CY-MAB 167.98 ± 11.53        0.23 ± 0.01 -43.93 ± 3.38 86.01 ± 3.02 184.16 ± 47.43 
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Figure 16: Visualization of the liposomes using AFM. LipTS incubated at 37 °C (A), LipTS-GD at 
37 °C (B), LipTS-GD after UHF-MRI exposure (C), LipTS-GD-CY-MAB at 37 °C (D) and  
LipTS-GD-CY-MAB after UHF-MRI exposure. Images on the right side show a cross-sectional profile 
of the identified lines of addressed sections in AFM images for addressing surface roughness. 
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3.4. Transmission electron microscopy 
 
Transmission electron microscopy (TEM) analysis was performed to further inspect 
morphological aspects, confirm the structure of the liposome as well as to investigate the exact 
deposition of the Gd-chelate within the liposomes. LipTS (A), LipTS-GD (B), and LipTS-GD-CY-MAB 
(D) showed round spherical vesicles at 37 °C. 
 LipTS appears under TEM without any dark contrast, whereas in the case of LipTS-GD and     
LipTS-GD-CY-MAB, a clear deposition of Gd is showing as dark contrast. Liposomes with  
Gd-chelate displayed good-segregated vesicles and no Gd-chelate was observed outside the 
liposomal domain, indicating that Gd-chelate was well encapsulated within the liposomes 
[149]. As shown in (Figure17 B, D). Gd is shown to be highly encapsulated in the core of the 
liposomes, as the lipid bilayer incorporated chelate is holding the Gd. 
The temperature dependent stability of the vesicles in the presence of Gd-chelate was observed 
after hyperthermia application using UHF-MRI, where vesicular deformation of the liposomes 
was evident and Gd-chelate was released (Figure 17 C, E). This confirms the results indicated 
by Hardiansyah et al. [155] in which he reported that magnetically induced hyperthermia 
triggers disruption of the lipid bilayer, hence facilitate the release of the encapsulated moieties. 
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Figure 17: Temperature-dependent transmission electron micrographs of LipTS (A), LipTS-GD 
(B) and LipTS-GD-CY-MAB (D) incubated at 37 °C manifested well-segregated vesicular structures 
and well-encapsulated of Gd in the liposomes. LipTS-GD after UHF-MRI exposure (C) and 
 LipTS-GD-CY-MAB after UHF-MRI exposure (E) demonstrated the release of Gd-chelate payload 
after disruption of the lipid bilayer of LipTS-GD and LipTS-GD-CY-MAB. 
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3.5. Differential scanning calorimetry 
 
Differential scanning calorimetry (DSC) experiments were carried out to determine the required 
temperature for the transformation from the liquid condensed to liquid expanded of the prepared 
liposomes. Thermosensitive properties of the liposomes and their phase transition temperature 
were depended on the subtle blend of the lipids. The phase transition temperature was 
determined for both LipTS-GD and LipTS-GD-CY-MAB. The first change in phase transition (onset 
temperature) for LipTS-GD was detected at about 38 °C and reached a maximum value of about 
42 °C (Figure 19 A). In the case of LipTS-GD-CY-MAB, the phase transition was detected at about 
38 °C and reached its maximum value at about 39 °C (Figure 19 B). LipTS-GD and                      
LipTS-GD-CY-MAB have almost the same onset thermal point, whereas LipTS-GD-CY-MAB showed 
lower temperature for the maximum value. 
The observed decrease in the phase transition temperature in LipTS-GD-CY-MAB is mainly related 
to the increased cholesterol molar ratio in the formulation. Cholesterol can be integrated within 
the phospholipids membrane. It reduces the enthalpy of the phase transition of the 
phospholipids membrane or at higher concentrations, it can eliminate it [123]. It fluidizes the 
phospholipid membrane in the liquid condensed by inhibition of the align configuration of acyl 
chains [60] (Figure 18). Therefore, liposomes with high cholesterol concentration may lose 
their thermosensitive properties. It increases the packing density of phospholipids in the liquid 
expanded phase. Consequently, membrane permeability is altered depending on the ration and 
concentration of cholesterol [60,156].  
 
 
 
 
Figure 18: Influence of cholesterol on the liquid condensed phase in the phospholipid 
membrane. Cholesterol between the acyl group causes fluidization of the lipid membrane. 
 
 
59 
 
Many thermosensitive liposomal formulations reported in the literature showed 
thermosensitivity in the range of 43-45 °C [157,56]. Needham et.al  has previously reported 
liposomes with mild thermosensitivity that showed a phase transition temperature of 39-40 °C 
[57]. Our prepared liposomes showed high thermosensitivity with low phase transition 
temperature starting at about 38 °C, indicating rapid thermosensitive properties with high 
thermosensitivity. The required temperature for our nanocarrier system can be achieved under 
UHF-MRI exposure. This facilitates the beneficial aspects of hyperthermia treatment without 
harming neighboring tissues.  
 
 
 
Figure 19: Differential scanning calorimetry thermogram of LipTS-GD (A) and LipTS-GD-CY-MAB.             
Cells filled with buffer were utilized as references.  
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3.6. In vitro drug release 
 
As a proof of concept for the thermosensitive properties of the prepared liposomes, the DOX 
release profile from our liposomes upon hyperthermia was obtained. An active response of the 
liposomes upon low hyperthermia was observed, which indicates that the low hyperthermia 
subjected the liposomes to a phase transition from liquid condensed to liquid expanded phase 
[65,158,159]. 
 Release profile from LipTS-GD and LipTS-GD-CY-MAB was performed at 37, 38, 39 and 40 °C 
(Figure 20 A, B) for different time intervals using the dialysis bag technique. No significant 
release was observed at 37 °C in LipTS-GD and LipTS-GD-CY-MAB, which indicate the liposomes 
were mostly intact at normal physiological temperatures. However, DOX release started at         
38 °C. 
The maximum amount of DOX was released (about 82 %) from LipTS-GD after one hour at          
40 °C. Moreover, 60 % of DOX was released after one hour of temperature treatment at 39 °C. 
DOX release profile showed a slow blunt increase to reach its maximum release capability, 
which is ascribed to the low hyperthermia treatment. As reported previously by Gaber et al. 
[53,57] their thermosensitive liposomes took 30 min to release ∼40 % of its contents.                    
de Smet et al. previously reported DOX release from low thermosensitive liposomes with a 
very sharp release of about 90 % after 5 min of treatment at 42 °C [65]. Thus indicating that 
high-temperature treatment exceeding 40 °C can result in higher sharpness regarding 
thermosensitive liposomes content release.   
A release profile for LipTS-GD-CY-MAB was obtained (Figure 20 B) following the same parameters 
as LipTS-GD (Figure 20 A). Results were comparable with those obtained from LipTS-GD with a 
slight observed increase. The release reaching its maximum of about 78 % and 88 % after one 
hour of treatment at 39 and 40 °C, respectively. This increase can be ascribed to higher 
cholesterol content in LipTS-GD-CY-MAB as the phase transition temperature is decreased, 
therefore, the disruption of the liposomal bilayer is faster and subsequently, the cargo release is 
faster.  
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Figure 20: Time-dependent release of DOX from LipTS-GD (A) and LipTS-GD-CY-MAB (B) at various 
temperatures (37, 38, 39 and 40 °C). DOX release was plotted as an average of percentages ± 
SD of three independent experiments and the release of DOX within the first 60 min was 
measured. 
A 
B 
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3.7. Ultra high magnetic resonance imaging 
 
Gd-chelate is encapsulated in both LipTS-GD and LipTS-GD-CY-MAB thus giving these liposomes 
paramagnetic properties, to facilitate imaging mediated DOX delivery. Furthermore, in order to 
further understand and quantify the changes in the relaxation rate R1 of the liposomes, MR 
images and T1 quantification was performed. R1 was determined by measuring the relaxation 
time T1 at different dilutions of Gd-chelate before and after heating above Tm (T > Tm). The 
contrast of LipTS-GD was low before heating, thus correlates with the results obtained by TEM 
image (Figure 17 B) which visualized Gd-chelate to be in the aqueous payload of the liposomes.  
The contrast is decreased because of the restricted water exchange between the outer and inner 
liposomal domains. After heating of LipTS-GD, Gd-chelate was released and higher water 
exchange was achieved, therefore, higher contrast was observed in Figure 21 A. Figure 21 B 
represents the relaxation rate of LipTS-GD plotted against different Gd-chelate concentrations. 
Relaxivity r1 before heating can be obtained from the slope of the black line and r1 after heating 
is obtained from the slope of the red line. Where r1 before heating is 3.10 ± 0.5 s-1 mM-1 and 
r1 after heating is 4.01 ± 0.58 s-1 mM-1 (Figure 21 B).  
It is observed that the release of the hydrophilic Gd-chelate is triggered at T > Tm, as R1 is 
increased after heating. The phospholipid layer surrounding the incorporated Gd-chelate 
hinders diffusion and exchange of water between the inner and outer compartments of 
liposomes, therefore, the longitudinal relaxation rate is increased after heating [160]. Indicating 
that Gd-chelate was successfully released after heating and higher water exchange was available 
from both the surrounding buffer and from the buffer entering the aqueous lumen of the 
liposomes, hence increasing the relaxation rate.  
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Figure 21: UHF-MRI images of different concentrations of Gd-chelate before and after heating 
of Lip TS-GD at T > Tm (A). UHF-MRI relaxation rates were measured at different dilutions of 
Gd-chelate before and after heating (T > Tm) (B). It represents the slope of the fitted linear plot 
before (black) r1= 3.10 ± 0.5 s-1 mM-1 (Gd) and after heating (red) r1 = 4.01 ± 0.58 s-1 mM-1 
(Gd). 
 
Moreover, evaluation of the paramagnetic properties of the LipTS-GD-CY-MAB was conducted, T1 
weighted images of LipTS-GD-CY-MAB with different Gd-chelate dilutions before and after heating 
have higher contrast (Figure 22 A).  
These results correspond with the results obtained from TEM images, as the Gd-chelate in 
LipTS-GD-CY-MAB appears to be positioned in the lipid bilayer and protruding on the liposomal 
surface. Therefore, the possibility of water exchange is higher, thereafter, a more pronounced 
A 
B 
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contrast is observed. The relaxation rate R1 was determined after measuring relaxation time T1 
at different dilutions of Gd-chelate before and after heating above Tm ( T > Tm).  
Relativity r1 before and after heating is determined from the slope (Figure 22 B), where r1 
before heating is 4.91 ± 0.15 s-1 mM-1 and r1 after heating is 7.98 ±1.24 s-1 mM-1. An increment 
in r1 was observed after heating indicating a successful lipid bilayer destruction at T > Tm, 
which enabled water crossing throughout the disrupted membrane. 
 
 
 
 
 
 
Figure 22: UHF-MRI images of different concentrations of Gd-chelate of LipTS-GD-CY-MAB before 
and after heating (A). UHF-MRI relaxation rates measured at different dilutions of Gd-chelate 
before and after heating (T > Tm) (B). Slope of the fitted linear plot before heating (black) 
r1=4.91 ± 0.15 s-1 mM-1 (Gd) and after heating (red) r1= 7.98 ±1.24 s-1 mM-1 (Gd). 
A 
B 
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These findings correspond with previously published results by de Smet et al. [65] and 
Fossheim et al. [159], who studied the feasibility of Gd-DTPA encapsulation in liposomes and 
the triggered release of Gd-chelate from liposomes, respectively. In both works, there was an 
increase in r1 as the temperature reached Tm. T1 weighted images of liposomes with different 
Gd-chelate concentrations after heating appeared with higher contrast. The longitudinal 
relaxivity of the liposomal encapsulated paramagnetic MRI contrast agent is regulated by the 
water diffusion across the phospholipid bilayer that increases with temperature increase. 
Regarding the cellular internalizing cell receptors, it has been reported that the longitudinal 
relaxivity r1 is regulated and can be modified by cellular compartmentalization effects. 
Therefore, an efficient r1 does not only help inducing hyperthermia but can as well provide 
promising opportunities to observe and record the biological fate of liposomes either in vitro or 
in vivo [161]. 
 
 
3.8. Cytotoxicity studies upon hyperthermia 
 
MTT assay was used to determine the cell viability after treatment with DOX-liposomes. Cell 
toxicity experiments were investigated against MDA-MB-231-ctrl cells obtaining 
overexpression of ADAM8 on their cell surface. To investigate the optimum incubation 
conditions, cells were incubated with LipTS-GD for 3 or 3.5 hours at 37 °C followed by thermal 
therapy at 40 °C or cellular exposure to commercially available UHF-MRI field for 30 or           
60 min (Figure 23). 
Cells treated at 37 °C showed cellular viability of about 85 % proving that the liposomes are 
mostly intact at normal physiological temperature. This correlates with the results obtained by 
DSC thermogram (Figure 19 A) as the first detected change in temperature of LipTS-GD was at 
about 38 °C and with DOX release profile (Figure 20 A). The cellular toxicity obtained after 
37 °C treatment can either be explained by minor liposomal DOX lumen leakage or by the 
endocytosis events of DOX-liposomes in the cells independent of the triggered release. Our 
DDS shows low toxicity at 37 °C, whereas DOX low-temperature sensitive liposomes with cell 
viability < 40 % at 37 °C were reported by de Smet et al. [65]. Cells treated at 38 °C manifested 
a decrease in cellular viability to 77 % and 63 % after 30 min and 60 min of thermal treatment, 
respectively. Consequently, we can conclude that the LipTS-GD portrays high thermosensitivity. 
At 39 °C and 40 °C thermal treatment, a reduction in cellular viability was observed to  
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67 % or 51 % and 45 % or 31 % after 30 or 60 min of treatment was observed, respectively. 
This indicates that the release of DOX from our liposomes is only triggered upon hyperthermia. 
This correlates with the results obtained from the release studies displaying a gradual constant 
release of DOX in correlation with temperature and time increase. After 30 or 60 min treatment 
under UHF-MRI, cells exhibited cellular viability of 49 % and 36 %, which is comparable to 
cellular viability after thermal treatment at 40 °C.  
Temperature of samples with LipTS-GD was measured after UHF-MRI exposure using IR 
thermometer and it recorded 38.5 ± 0.3 °C.  Thus using a UHF-MRI could be used to induce 
hyperthermia slightly higher than the physiological temperature in a tumor location. Cell 
viability in UHF-MRI correlated with temperature and exposure time. 
Thermosensitive liposomes exhibit preferable characteristics in cancer treatment as they 
provide a more effective accumulation of DOX within the nuclear domain [140]. This can be 
attributed to the endocytotic thermo-triggered release of liposomal DOX-payload after cellular 
localization, these results are consistent with that described by Pan et al. [162]. This correlates 
with magnetic hyperthermia induced by MRI [104-106,163] and enhanced cellular uptake of 
magnetic particles under the magnetic field as previously reported [164-166]. 
 
Figure 23: Temperature-dependent cytotoxicity of DOX-LipTS-GD. MDA-MB-231 were 
incubated with LipTS-GD liposomes for 3 or 3.5 hours at 37 °C followed by thermal therapy or 
cellular exposure to UHF-MRI field for 60 or 30 minutes. Data is expressed as the mean ± SD. 
For statistical analysis the results were compared against the results of treated cells at 37°C. 
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Moreover, the evaluation of the cellular viability for LipoTS-GD has enabled us to choose the 
optimal thermal treatment time span for the additionally modified liposomes, i.e., LipTS-GD-CY 
and LipTS-GD-CY-MAB. The chosen thermal treatment time was set at 60 min, depending on the 
previous results. 
Cytotoxicity for LipTS-GD-CY and LipTS-GD-CY-MAB were also carried out on MDA-MB-231-ctrl 
cells. Cells were incubated for 3 hours at 37 °C followed by thermal therapy or cellular exposure 
to commercially available UHF-MRI field for 60 min (Figure 24). Furthermore, cellular 
cytotoxicity experiments were carried out in MDA-MB-231-ctrl cells to evaluate the 
contribution of targeting features implemented by DOX-LipTS-GD-CY and DOX-LipTS-GD-CY-MAB 
(targeting of ADAM8 receptors, and magnetic hyperthermia targeting). Both liposomal 
formulations (LipTS-GD-CY and LipTS-GD-CY-MAB) were evaluated under the presence and absence 
of hyperthermia or UHF-MRI exposure. Cellular cytotoxicity was low at 37 °C, with cellular 
viability of 85 % in the case of DOX-LipTS-GD-CY and 80 % in the case of DOX-LipTS-GD-CY-MAB, 
this can be ascribed to DOX lumen leakage or by the endocytosis events of DOX-liposomes in 
the cells as described above. Thus indicating that the incorporation of cyanur or/and the cellular 
modification did not affect the drug release from liposomes at normal physiological 
temperature. The integrity of the liposomal formulation is rather intact at 37 °C. As shown by 
the DSC thermogram for LipTS-GD-CY-MAB, the recorded phase transition temperature Tm is about 
39 °C. Thus allow higher cellular toxicity at a temperature slightly higher than the physiological 
temperature. At 38 °C thermal treatment cellular viability decreased around 20 % from that 
obtained at 37 °C in both LipTS-GD-CY and LipTS-GD-CY-MAB, this points out the high 
thermosensitivity and rapid liposomal response to a slight change in temperature. At 39 °C and 
40 °C cells showed a significant reduction in cellular viability to 48 % and 32 % in the case of 
LipTS-GD-CY, and 41 % and 27 % in the case of LipTS-GD-CY-MAB, respectively.  
Temperatures of samples with LipTS-GD-CY and LipTS-GD-CY-MAB were measured after UHF-MRI 
exposure by IR thermometer and 38.6 ± 0.3 °C was recorded. Moreover, after thermal treatment 
under UHF-MRI, cellular viability was 36 % and 29 % in the case of DOX-LipTS-GD-CY and 
DOX-LipTS-GD-CY-MAB, respectively. DOX-liposomes cytotoxicity after 60 min under UHF-MRI 
exposure showed a good correlation to the surviving fraction obtained at 40 °C. This correlates 
with magnetic hyperthermia induced by UHF-MRI and elevated cellular uptake under the 
magnetic field as reported by Venugopal et al. [165]. The increased uptake under the magnetic 
field is ascribed to either energy-dependent endocytotic events or a simple pulling of the 
magnetic nanocarrier into the cell by magnetic force [166].  
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Thus, confirming the thermosensitive feasibility of the prepared liposomes as a triggerable 
nanocarrier. When comparing DOX-LipTS-GD-Cy and DOX-LipTS-GD-CY-MAB, the highest 
cytotoxicity was observed after the combination of targeting and magnetic hyperthermia. These 
results correlate with previous reports by Laginha et al. [167] and Venugopal et al.[165], who 
have observed an increased in cytotoxicity when facilitating magnetic hyperthermia. 
We hypothesized that the incorporation of MAB 1031 into liposomes slightly increased the 
cellular internalization, as can be observed by the increased cellular cytotoxicity. This supports 
the previous suggestion that targeted liposomes displayed higher cytotoxicity to its non-targeted 
counterparts [168]. Moreover, these findings implement that immuno targeting and magnetic 
induced hyperthermia are synergically performing for the enhancement of cellular uptake and 
cytotoxicity [169,170]. 
 
 
Figure 24: Temperature-dependent cytotoxicity of DOX-LipTS-GD-CY and DOX-LipTS-GD-CY-MAB. 
MDA-MB-231-ctrl were incubated with LipTS-GD-CY or DOX-LipTS-GD-CY-MAB liposomes for             
3 h at 37 °C followed by thermal therapy or cellular exposure to UHF-MRI for 60 min. Data is 
expressed as the mean ± SD. For statistical analysis, the results were compared against the 
results of treated cells at 37 °C. 
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3.9. Cellular uptake evaluation 
 
The ability of the nanocarrier system to load DOX preferentially inside the cellular 
compartment makes it available to exert its cytotoxic effects. The cellular uptake studies of 
DOX were performed on MDA-MB 231-ctrl cells and the internalization and the subcellular 
localization of DOX were visualized using confocal laser scanning microscope (CLSM)        
(Figure 25). DAPI was used to counterstain the nuclei for cell visualization under CLSM. 
Results were compared with free DOX uptake at 37 °C, which appears to be localized in the 
nuclear area [171]. As expected, a minor release of DOX was achieved after incubating the 
LipTS-GD at 37 °C, and its uptake was less pronounced than at 40 °C. Hence, it showed minimal 
uptake (Figure 25). Cells after thermal and UHF-MRI treatments rendered strong red 
fluorescence indicating that the liposomes are intranuclearly internalized by  
MDA-MB 231-ctrl. The observed increase in cellular uptake of DOX at 40 °C closely correlates 
to the enhanced DOX release as previously discussed. DOX-LipTS-GD after UHF-MRI exposure 
prevailed a reasonable enhancement in DOX distribution throughout the cellular compartments. 
Cells appear oval to spherical in shape, indicating cytotoxicity induced by apoptosis. This 
correlates with the appearance of the cells incubated with free DOX. The varying fluorescence 
intensity indicates that the uptake was enhanced in the presence of an external magnetic field 
as previously reported [172,173]. The enhanced cellular uptake under magnetic exposure can 
be attributed to an energy-dependent endocytic event or the liposomes are just pulled directly 
into the cells by the force of the magnetic field [166]. 
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Figure 25: Temperature-dependent confocal laser scanning acquisitions of MDA-MB-231-ctrl 
cells treated with DOX LipTS-GD or free DOX. Scale bar represents 10 µm. 
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3.10. Pathway studies 
 
Liposomes interact with the cell membrane in different mechanisms; they either adsorb to the 
cellular surface and the subsequently released drug would be uptake into the liposomal 
membrane by simple diffusion. They can simply fuse with the cellular membrane, owing to that 
both membranes - liposomal and cellular - are similar in their component and functionality. 
Another possibility is the exchange of the lipids between the liposomal membrane and the 
cellular membrane after the liposomes adhesion to the cellular membrane. The last and most 
common possibility of cellular uptake for the liposomes is endocytosis [174].  
Active endocytosis is comprised of several pathways: clathrin-mediated endocytosis (CME), 
caveolin-dependent endocytosis, and others that have been reported recently including 
transmembrane penetration [175].  
Moreover, CME can be classified as non-specific adsorption uptake, which occurs due to 
hydrophobic or electrostatic interactions that facilitate the internalization process. Or receptor-
mediated uptake that carries out the uptake of the nanocarriers that is modified with a specific 
ligand) after their binding to receptors on the cell surface. This binding triggers the cellular 
plasma membrane, which forms “coated pits” that subsequently enable the uptake of the 
liposomes into the cells [176]. 
To further assess the mechanism of liposomal internalization and cellular uptake of LipTS-GD-CY 
and LipTS-GD-CY-MAB into MDA-MB-231-ctrl cells, endocytotic pathways were investigated. 
Filipin III and chlorpromazine were employed to inhibit the caveolae-mediated and clathrin-
mediated endocytosis, respectively (Figure 26). Cells treated with LipTS-GD-CY and  
LipTS-GD-CY-MAB under UHF-MRI without pathway inhibition exerted comparable cytotoxicity 
as previously described (Figure 24). Pre-incubation with filipin III showed minor inhibition of 
liposomal uptake.  
Pre-incubation with chlorpromazine inhibited the uptake of both LipTS-GD-CY and  
LipTS-GD-CY-MAB. The notable effect of chlorpromazine inhibition indicates that cellular uptake 
occurs predominantly by clathrin-mediated endocytosis. These results correspond with 
previously reported works stating that spheres < 200 nm in size are mainly taken up into the 
cells by the formation of clathrin-coated pits [177,178].  
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On another note, LipTS-GD-CY-MAB exhibited less cellular viability, so it can be assumed that the 
antibody-mediated endocytosis plays a role in the internalization of MAB decorated liposomes 
[179]. Cells treated with LipTS-GD and LipTS-GD-MAB at 37 °C exhibited low toxicity with or 
without inhibition. 
 
 
 
Figure 26: Cell viability of MDA-MB-231-ctrl cells after incubation with LipTS-GD-CY and                       
LipTS-GD-CY-MAB in the presence of two pathway inhibitors (filipin III or chlorpromazine) 
with/without UHF-MRI exposure. Blank represents cells without inhibitors. For statistical 
analysis, results were compared with treated blank cells with the same conditions. 
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3.11. Mechanism of endosomal escape by fluorescence microscopy 
 
A successful endosomal escape is important for the release of cargo from a nanoscaled carrier. 
Therefore, to check the role of ligand-gated antibody against ADAM8 antigen, endosomal 
escape was investigated in MDA-MB231-ctrl and MDA-MB-231-rna cell lines. The cells were 
treated with NBD-labelled (green) liposomal formulations (LipTS-GD-CY-MAB and LipTS-GD-CY).  
Figure 27 depicted that higher green fluorescence signals were obtained from the cells 
incubated with the ADAM8 antibody tagged liposomes, showing the ligand-specific targeting 
of the antibody to the cells. In addition, to further characterize the intracellular trafficking, the 
co-localization mechanism using a lysosomal marker (Lyso Tracker® red-DND 99) was used. 
It was observed that the targeting by ADAM8 antibody significantly enhanced the  
co-localization of liposomes within the lysosomes, which leads to a yellow color as shown by 
Guo et al.[180] and efficient release of cargo into the cytosol without any lysosomal 
degradation. On the other hand, NBD-LipTS-GD-CY, showed a negligible endosomal escape, 
suggesting the contribution of ADAM8 antibody in the facilitation of endocytosis and 
endosomal release. These results indicate the previous report by Mortensen et al. [181], which 
explains that the incorporation of the antibody to the liposomes would selectively increase the 
cellular internalization due to antibody binding to cellular surface. 
To evaluate the active targeting by our nanocarrier system, MDA-MB-231-rna cells were 
incubated with NBD-labelled (green) liposomal formulations (LipTS-GD-CY and LipTS-GD-CY-MAB). 
It has been observed that lower green fluorescence signals were obtained from the cells 
incubated with the ADAM8 antibody tagged liposomes, which indicated that the ligand-specific 
targeting of the antibody can only be accomplished by the presence of specific receptor sites.  
The results of figure 28 also showed a decreased co-localization of liposomes and the lysosomal 
vicinity further confirming the lower cellular uptake of the carrier system.  
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Figure 27: Endosomal escape of NBD labeled liposomal formulation with or without MAB1031 
against MDA-MB-231-ctrl cells, using fluorescence microscopy. Blue channel depicting the 
nuclei staining, while the red fluorescence represents the lysosomes. Green signals depicting 
the NBD labeled liposomes. Colocalization of the liposome within the lysosomes indicated by 
yellow color. Scale bar 20µm. 
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Figure 28: Endosomal escape of NBD labeled liposomal formulation with or without  
MAB 1031 against MDA-MB-231-rna cells, using fluorescence microscopy. Blue channel 
depicting the nuclei staining, while the red fluorescence represents the lysosomes. Green 
signals depicting the NBD labeled liposomes. Colocalization of the liposome within the 
lysosomes indicated by yellow color. Scale bar 50µm. 
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3.12. In vitro evaluation of ADAM8 targeting by immunoliposomes 
 
Commercially available nontargeting liposomal DOX formulations (e.g. Doxil®) manifest an 
enhanced safety profile compared to conventional chemotherapy and exhibit little adverse 
effects. However, these FDA approved chemotherapeutics fail to exhibit enhanced clinical 
benefits in treating TNBC due to their lack of specific targeting to the tumor tissues [182]. 
Consequently, a delivery system to specifically target the TNBC is the need of time to overcome 
the demerits, as mentioned above. One of the approaches to achieve targeting to the TNBC cells 
in their solid tumors or circulating cells (metastatic) is the use of cellular modified liposomes. 
One of the major modification for targeting is the PEGylation of liposomes, as the PEGylation 
achieve long-circulating liposomes allowing higher accumulation of the liposomes in the solid 
tumors by EPR effect. One the other hand, EPR effect is hampered by the disrupted vascularity 
system of the tumor as well as it lacks the ability to target circulating cells or normally 
vascularized tumors. For a more efficient active targeting of TNBC, liposomes can be surface 
modified by the conjugation of therapeutic ligands, e.g. aptamers, or by the conjugation of 
antibodies.  
 
 
3.12.1. Cellular binding investigation using washing method  
 
MDA-MB-231-ctrl and MDA-MB-231-rna cells were treated with NBD-LipTS-GD-CY-MAB and 
NBD-LipTS-GD-CY for 2 h at 4 °C to prevent any endocytotic events as the main object of this 
experiment was to evaluate the cellular binding capabilities of the modified / non-modified 
liposomes regardless of the endocytosis. NBD-PE was used as a colored lipid that allows 
fluorescence imaging of the treated cells with the liposomes. This would not only allow imaging 
it would as well allow quantification of the liposomal binding by the fluorescence intensity. In 
the case of MDA-MB-231-ctrl cells, an increment in NBD fluorescence in the case of           
LipTS-GD-CY-MAB in comparison with its non-targeted counterpart (LipTS-GD-CY) was observed, 
indicating effective cellular binding (Figure 29A) [75]. In the case of MDA-MB-231-rna cells, 
the absence of ADAM8 receptor deprived the LipTS-GD-CY-MAB to specifically target the cells that 
further confirming the lock key phenomenon of ligand-specific binding (Figure 30). Moreover, 
in the case of LipTS-GD-CY no significant binding was achieved (Figure 29).  
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Notably, the overexpressed ADAM8 ectodomain on the cellular surface of MDA-MB-231-ctrl 
cells is responsible for selective binding of LipTS-GD-CY-MAB. These results correlate with a 
previous report presenting MAB 1031 as a therapeutic target of ADAM8 for TNBC cells [113]. 
An efficient binding may contribute to ADAM8 inhibition and therefore decrease tumor 
adhesion, metastasis, and dissemination. Furthermore, the fluorescence intensity of the cellular 
binding was quantified using fluorescence intensity reader (Figure 29B), the quantified 
fluorescence intensity of the binding of LipTS-GD-CY-MAB was the highest to MDA-MB-231-ctrl 
indicating the targetability of the MAB 1031 modified liposomes to the ADAM8 positive cells.  
 
 
 
 
Figure 29: Binding efficiency of NBD labeled liposomal formulations LipTS-GD-CY-MAB and    
LipTS-GD-CY on MDA-MB-231-ctrl cells (A). Green signals depicting the NBD labeled liposomes. 
Higher green fluorescence depicting the enhanced cellular binding of the liposomes. Scale bar 
represents 20 μm. Quantitative determination of the binding efficiency of NBD labeled 
liposomal formulation LipTS-GD-CY-MAB and LipTS-GD-CY on MDA-MB-231 cells (B). 
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Figure 30: Binding efficiency of NBD labeled liposomal formulations LipTS-GD-CY-MAB and    
LipTS-GD-CY on MDA-MB-231-rna cells (A). Green signals depicting the NBD labeled liposomes. 
The green fluorescence depicting the cellular binding of the liposomes. Scale bar represents 20 
μm. Quantitative determination of the binding efficiency of NBD labeled liposomal formulation 
LipTS-GD-CY-MAB and LipTS-GD-CY on MDA-MB-231-rna cells (B). 
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3.12.2. Evaluation of cellular binding using washing method under UHF-MRI  
 
Both LipTS-GD-CY-MAB and LipTS-GD-CY obtain Gd in their composition. Gd-chelate is a contrast 
agent that would allow imaging as well as quantification of the cellular binding capabilities 
under UHF-MRI imaging. Presumably, liposomes with higher binding efficiency would 
illustrate higher contrast in the UHF-MRI images. While liposomes with less binding abilities 
would be washed out during the washing protocol, therefore, lesser amounts of Gd would be 
present and consequently lower contrast would be evident.  
As a proof of concept for the binding efficiency, MDA-MB-231-ctrl and MDA-MB-231-rna 
cells were treated with both LipTS-GD-CY-MAB and LipTS-GD-CY and UHF-MRI images were 
acquired after washing protocol. MDA-MB-231-ctrl cells treated with LipTS-GD-CY-MAB showed 
a significant contrast in comparison to its counterpart LipTS-GD-CY (Figure 31A, 32A), which 
indicate a higher binding efficiency. MDA-MB-231-rna treated with both the abovementioned 
liposomes showed no noticeable contrast under UHF-MRI, thus represents a lesser Gd 
concentration in the treated area, which proves that less cellular binding was achieved.  
Additionally, the mean gray value of the cellular binding was measured, the mean gray value 
of the binding of LipTS-GD-CY-MAB was the highest in MDA-MB-231-ctrl (Figure 31B) indicating 
the targetability of the MAB 1031 modified liposomes to the ADAM8 positive overexpression 
cells. The noticeable availability of Gd serves as proof of the significant enhancement in  
LipTS-GD-CY-MAB binding after incorporation of MAB 1031 antibody. Whereas, no significant 
gray value has been observed in the case of MDA-MB-231-rna cells for both liposomal 
formulations. Thereupon, LipTS-GD-CY-MAB could be used for diagnostic targeted imaging of solid 
tumors and metastatic cells under UHF-MRI.  
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Figure 31: Binding efficiency of LipTS-GD-CY-MAB and LipTS-GD-CY on MDA-MB-23-ctrl cells, 
under UHF-MRI (A), scale bar represents 4 μm. The mean gray value of the binding efficiency 
of LipTS-GD-CY-MAB and LipTS-GD-CY on MDA-MB-231-ctrl cells (B). 
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Figure 32: Binding efficiency of LipTS-GD-CY-MAB and LipTS-GD-CY on MDA-MB-23-rna cells, 
under UHF-MRI, scale bar represents 4 μm (A). The mean gray value of the binding efficiency 
of LipTS-GD-CY-MAB and LipTS-GD-CY on MDA-MB-231-rna cells (B). 
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3.13. Circulation method 
 
 
The circulation method represents an approach for mimicking cellular binding while the 
liposomes are circulating in the bloodstream. NBD-labeled LipTS-GD-CY-MAB and LipTS-GD-CY 
were used to detect the binding efficiency of the liposomes using the circulation method. 
Fluorescence microscopy images of LipTS-GD-CY-MAB and LipTS-GD-CY depicted that a higher 
green fluorescence signal was obtained from the MDA-MB-231-ctrl cells incubated with the 
LipTS-GD-CY-MAB antibody tagged liposomes (Figure 33A), showing the ligand-specific targeting 
of the antibody to the cell. However, fluorescence microscopy images obtained after incubating 
with LipTS-GD-CY-MAB or LipTS-GD-CY with MDA-MB-231-rna rendered a very slight green 
fluorescence signal (Figure 34A). Thus demonstrating that the knockdown of ADAM8 in 
MDA-MB-231-rna cells reduced the targetability of the liposomes. Likewise, high fluorescence 
intensity serves as an indication of the promising binding, hence cellular internalization, when 
utilizing these liposomes in vivo. It is observed that the LipTS-GD-CY-MAB tagging played a crucial 
role in binding with ADAM8 antigens present in MDA-MB-231-ctrl cell line. The results of 
the quantitative assay exhibited a significant (p < 0.001) increase in binding of LipTS-GD-CY-MAB 
tagged NBD liposome (Figure 33B). These results support the previously suggested results by 
Romangoli et al.[113], which proclaimed MAB 1031 as a therapeutic target for ADAM8. 
Moreover, non-significant binding was depicted in MDA-MB-231-rna cells (Figure 34B), the 
absence of ADAM8 receptor deprived the LipTS-GD-CY-MAB to specifically target the cells that 
further confirming the lock key phenomenon of ligand-specific binding.  
The results indicate that liposomes obtain high binding capability in a system that mimics blood 
circulation. This can be a sign of a promising binding for further in vivo applications for 
metastasis, in which blood circulating LipTS-GD-CY-MAB bind to the circulating metastatic 
ADAM8 overexpressed malignant tumor cells for further diagnosis (UHF-MRI imaging) and 
treatment by DOX delivery. 
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Figure 33: Binding efficiency of NBD labeled liposomes LipTS-GD-CY-MAB and LipTS-GD-CY on                    
MDA-MB-231-ctr (A). Green signals depicting the NBD labeled liposomes. Higher green 
fluorescence depicting the enhanced cellular binding of the liposomes. Scale bar represents 
 20 μm. Quantitative determination of binding efficiency of NBD labeled liposomal formulation 
LipTS-GD-CY-MAB and LipTS-GD-CY on MDA-MB-231-ctrl cells (B). 
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Figure 34: Binding efficiency of NBD labeled liposomal formulations LipTS-GD-CY-MAB and  
LipTS-GD-CY on MDA-MB-231-rna cells (A). Green signals depicting the NBD labeled liposomes. 
The green fluorescence depicting the cellular binding of the liposomes. Scale bar represents 
 20 μm. Quantitative determination of binding efficiency of NBD labeled liposomal formulation 
LipTS-GD-CY-MAB and LipTS-GD-CY on MDA-MB-231-rna (B). 
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3.14. Hemocompatibility studies 
 
The inherent properties of liposomes increase their tolerability towards the encapsulated drugs, 
improves the subsequent therapeutic index after their administration as well as provide tolerable 
pharmaceutical formulations for those drugs which cannot be administrated in conventional 
approaches [183]. Liposomes are a great nanocarrier to carry and deliver pharmaceutical agents, 
which is challenging parenterally. This reflects the clinical relevance and importance of 
evaluating the systematic administration of liposomal formulation and assess their 
hemocompatibility. Our prepared liposomes are meant for parenteral application to provide 
long blood circulation times and to deliver DOX to tumor tissues. In order to ensure a high level 
of safety during this long journey of the prepared liposomes, hemocompatibility studies are of 
great importance. Blood is a mixture of components. The drug carrier should be compatible 
with all the blood constitutes. For more understanding of the interaction between the liposomes 
and the blood components, hemocompatibility studies were carried out. These studies are 
essential to estimate the liposome's utility and provide a better understanding of the in vivo 
liposomal behavior. Therefore, hemolysis and aPTT tests were carried out of the liposomal 
formulations.  
 
 
3.14.1. Hemolysis assay 
 
Hemocompatibility studies could help understand the correlation between in vitro and in vivo 
and are as well useful for the determination of safe concentration to be administered in an  
in vivo experiment. Hemolysis assay represents the amount of hemoglobin released from the 
erythrocytes upon the addition of liposomes. The hemoglobin released from the erythrocytes 
reacts with atmospheric oxygen, which forms oxyhemoglobin that can be determined 
spectrophotometrically at 540 nm [184]. 1 % Triton X-100® was used as controls and the 
absorbance values of Triton X-100® were considered as 100 % hemolysis, due to its complete 
hemolysis capability [185]. The hemolytic potentials of DOX-LipTS, DOX-LipTS-GD,             
LipTS-GD-CY, and LipTS-GD-CY-MAB were about 5 %. The hemolytic potentials can thus be neglected    
(Figure 35). 
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Figure 35: Hemolysis assay of LipTS, LipTS-GD, LipTS-GD-CY, LipTS-GD-CY-MAB encapsulated DOX at 
DOX concentration of 1 mg/5 mg lipids, and free DOX at a concentration of 1 mg/ml.            
Triton X-100® was used as a positive control in hemolysis assay, depending on its ability to lyse 
the cells. For statistical analysis, the results were compared to fresh blood plasma. 
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3.14.2. Activated partial thromboplastin time test 
 
Activated partial thromboplastin time test (aPTT) test was performed to determine the change 
of the blood coagulation time upon exposure to liposomes. This test donates an in vitro test for 
a better understanding of in vivo application. aPTT test gives an insight into the effect of the 
liposomes on blood coagulation time. Results showed that the coagulation time for blood 
plasma was 30.4 S. The coagulation time increased to around 37.2 s for DOX-LipTS and 37.6 s 
for DOX-LipTS-GD. In the case of  DOX-LipTS-GD-CY and DOX-LipTS-GD-CY-MAB the coagulation 
times were 37.5 and 38.4 s, respectively. Free DOX obtained a coagulation time of 50.8 s and 
these are considered acceptable values for aPTT (Figure 36). An aPTT higher than 70 s implies 
continuous bleeding leaving the patient with a risk of hemorrhage as reported by Lee et al.[145]. 
These results indicate that the prepared liposomes can be administered intravenously. 
 
 
 
Figure 36: aPTT assay of LipTS, LipTS-GD, LipTS-GD-CY, LipTS-GD-CY-MAB encapsulated DOX at 
DOX concentration of 1 mg/5 mg lipids, and free DOX at a concentration of 1 mg/ml. Values 
between 30 and 40 s are considered acceptable. Blood plasma was used as a control. For 
statistical analysis, the results were compared to fresh blood plasma.  
88 
 
3.15. Chorioallantoic membrane  
 
In order to evaluate systemic biocompatibility, liposomes were administered intravenously into 
chick embryos to assess toxicity due to their systemic exposure [186]. Free DOX,                   
DOX-LipTS-GD-CY, and DOX-LipTS-GD-CY-MAB were injected intravenously on egg development 
day 11 (EDD 11). The heartbeat and the state of vessel development were monitored and 
recorded daily until EDD 16 to evaluate the cytotoxic effect of the administered liposomes. 
Free DOX showed a major cytotoxic effect with chick viability of only 40 % on EDD 16, 
whereas the chick viability in the case of DOX-LipTS-GD-CY and DOX-LipTS-GD-CY-MAB was          
87 % and 74 %, respectively (Figure 37). The model system of CAM is considered vulnerable, 
however, it has withstood the liposomal treatment protocol under normal physiological 
conditions with minimum or no intervention to its physiology, indicating that the liposomes are 
safe for further in vivo experiments. This investigation can be used as a proof of concept that 
DOX liposomes remained intact at normal physiological temperatures.  
 In other experiments, LipTS-GDCY-MAB was injected into the chick embryo vasculature on EDD 
11 and scanned under UHF-MRI to evaluate the magnetic properties of the liposomes in a 
biological system with T2-weighted images (3D) (Figure 38). LipTS-GD-CY-MAB had clear 
magnetic properties under UHF-MRI and the chick survived the scan. As well as chick embryo 
showed high viability at 37 °C for 6 days indicating the safety of our nanoscale carrier. 
The UHF-MRI offered anatomical information about the chick embryo. UHF-MRI                     
T2-weighted images did not only offer anatomical information and information about embryo 
development, but it is also a great non-invasive technique to observe and detect the localization 
of the liposomes in a biological system that offers high-resolution images. On the other hand, 
UHF-MRI can be used to detect metastatic dissemination. In order to reduce metastasis-related 
mortality, an early, as well as a selective detection, is required. Metastatic dissemination is a 
complex process, and once the cells are circulating in the system, their identification is quite 
difficult [187]. 
Introducing a nanocarrier that would allow an active targeting selectively to the ADAM8 
overexpressing cancer cells, a chemotherapeutic agent as well as an imaging agent that would 
allow the acquisition of UHF-MRI images. This facilitates the treatment of metastatic cancer 
as well as offers a deeper understanding of the metastasis dissemination. As a model for imaging 
mediated delivery of the nanocarrier, imaging the liposomal localization was obtained in a chick 
embryo. The chick embryo is healthy and no tumor model could be achieved within it. 
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Therefore, as observed from the contrast, LipTS-GD-CY-MAB are circulating in the whole body of 
the chick embryo and is not localized in a specific tumor region. This can be a promising 
approach to obtain an imagining mediated drug delivery system for the detection and treatment 
of tumors and metastatic cells. 
 
 
 
Figure 37: Chick embryo viability after injection of DOX-LipTS-GD-CY, LipTS-GD-CY-MAB and free 
DOX in 15 eggs for each of the samples at normal physiological conditions. Results showed no 
remarkable toxicity for DOX-liposomes; whereas, free DOX was used as control. 
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Figure 38: T2-weighted 3D image of a living chick embryo after administration of                   
LipTS-GD-CY-MAB under UHF-MRI.  
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4. Summary and outlook 
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4.1. Summary and outlook 
 
The present work describes the encapsulation of the drug doxorubicin (DOX) in immuno 
paramagnetic thermosensitive liposomes. DOX is the most common chemotherapeutic agent 
for the treatment of a variety of carcinomas. However, the pure drug has high cytotoxicity and 
therefore requires a targeted and biocompatible delivery system. 
The introduction includes concepts, modalities, and functionalities of the project. First,  
a detailed description of the cell type (triple-negative breast cancer) is given. Furthermore, the 
importance of liposomal doxorubicin is explained and the current state of research is shown. 
The importance of modification to achieve thermosensitive properties and the procedure for  
co-encapsulation with Gd chelate to achieve paramagnetic properties is also discussed. In 
addition, the first part describes the surface modification with ADAM8 antibodies, which leads 
to improved targeting. 
The second part of the thesis covers the different materials and methods used in this paper. The 
production of the liposomes LipTS, LipTS-GD, LipTS-GD-CY, LipTS-GD-CY-MAB and the loading of 
DOX using an ammonium sulfate gradient method were described in detail.  
The results part deals with the physicochemical characterization using dynamic light scattering 
and laser Doppler velocimetry, which confirmed a uniform monodisperse distribution of the 
liposomes. These properties facilitate the approach of liposomes to target cancer cells. The 
influence of lipid composition of liposomes, co-encapsulation with Gd chelate and surface 
modification of liposomes was evaluated and described accordingly. The size and structure of 
the individual liposomal formulations were determined by atomic force microscopy and 
transmission electron microscopy. Morphological examination of the liposomes confirmed 
agreement with the sizes obtained by dynamic light scattering. Temperature-dependent AFM 
images showed an intact liposome structure at 37 °C, whereas heating by UHF-MRI led to a 
lipid film indicating the destruction of the lipid bilayer. Furthermore, TEM images showed the 
morphological properties of the liposomes and gave a more precise indication of how                 
Gd-chelate accumulates within the liposomes. Liposomes with Gd-chelate showed well-
separated vesicles, suggesting that Gd- chelate is deposited in the lipid bilayer of the liposomes. 
Gd was encapsulated in the hydrophilic core whereas chelate was extended into the lipid 
bilayer. 
By differential scanning calorimetry and drug release, the heat-sensitive functionality of the 
liposomes could be determined. Liposomes showed a beginning of phase transition temperature 
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at about 38 °C, which can be achieved by UHF-MRI exposure. The maximum phase transition 
temperature in the case of LipTS-GD and LipTS-GD-CY-MAB was 42 °C and 40 °C, respectively. A 
proof of concept study for the thermosensitive properties of liposomes and a time-dependent 
DOX release profile in hyperthermia was performed. 
Gd-chelate is encapsulated in both LipTS-GD and LipTS-GD-CY-MAB and led to paramagnetic 
properties of the liposomes. This facilitates imaging mediated DOX delivery and diagnosis of 
the solid tumor and metastatic cells. The change in relaxation rate R1 of liposomes was 
quantified before and after heating above Tm (T> Tm). The relaxivity of the liposomes was 
obtained from the adapted slope of the relaxation rate against the Gd concentration. 
Remarkably, the relaxation rate and relaxivity increased after heating the liposomes above Tm 
(T> Tm), suggesting that the liposomes opened, released Gd chelate, and the exchange of water 
molecules became faster and more practicable. 
Toxicity studies describe the different mechanisms for induced DOX toxicity. The increased 
cytotoxic effect at elevated temperatures showed that the induced toxicity is thermally 
dependent, i.e. DOX was released from the liposomes. The high viability of the cells at 37 °C 
indicates that the liposomes were intact at normal physiological temperatures. Under UHF-MRI 
treatment, cell toxicity due to elevated temperature was observed. The cellular uptake of 
liposomes under UHF-MRI was followed by a confocal laser scanning microscope. An increase 
in fluorescence intensity was observed after UHF-MRI exposure. The study of the uptake 
pathway showed that the majority of liposomes were mainly uptake by clathrin-mediated 
endocytosis. 
In addition, the liposomes were modified with anti-ADAM8 antibodies (MAB 1031) to allow 
targeted delivery. The cellular binding capabilities of surface-modified and non-modified 
liposomes were tested on cells that had ADAM8 overexpression and on ADAM8 knockdown 
cells. Surface-modified liposomes showed a significant increase in binding ability, indicating 
significant targeting against cells that overexpress ADAM8 on their surface. In addition, cells 
with knockdown ADAM8 could not bind a significant amount of modified liposomes. 
The biocompatibility of liposomes was assessed using a hemolysis test, which showed 
neglected hemolytic potential and an activated thromboplastin time (aPTT), where liposomes 
showed minimal interference with blood clotting. Hemocompatibility studies may help to 
understand the correlation between in vitro and in vivo.  
The chorioallantois model was used in ovo to evaluate systematic biocompatibility in an 
alternative animal model. In the toxicity test, liposomes were injected intravenously into the 
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chicken embryo. The liposomes showed a neglectable harmful effect on embryo survival. While 
free DOX has a detrimental effect on the survival of chicken embryos, this confirms the safety 
profile of liposomes compared to free DOX. LipTS-GD-CY-MAB were injected into the vascular 
system of the chicken embryo on egg development day 11 and scanned under UHF-MRI to 
evaluate the magnetic properties of the liposomes in a biological system with T2-weighted 
images (3D). The liposomal formulation had distinct magnetic properties under UHF MRI and 
the chick survived the scan. 
In summary, immunomagnetic heat-sensitive liposomes are a novel drug for the treatment of 
TNBC. It is used both for the diagnosis and therapy of solid and metastasizing tumors without 
side effects on the neighboring tissue. 
Furthermore, a tumor in the CAM model will be established. Thereafter, the selective targeting 
of the liposomes will be visualized and quantitated using fluorescence and UHF-MRI. 
Liposomes are yet to be tested on mice as a xenograft triple-negative breast cancer model, in 
which further investigation on the effect of DOX-LipTS-GD-CY-MAB is evaluated. On one hand, 
the liposomes will be evaluated regarding their targetability and their selective binding. On the 
other hand, the triggered release of DOX from the liposomes after UHF-MRI exposure will be 
quantitated, as well as evaluate the DOX-Liposomes therapeutic effect on the tumor. 
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4.2. Zussamenfassung und Ausblick 
 
Die vorliegende Arbeit beschreibt die Verkapselung des Arzneistoffs Doxorubicin (DOX) in 
immunparamagnetische thermosensitive Liposomen. DOX ist das häufigste 
Chemotherapeutikum zur Behandlung einer Vielzahl von Karzinomen. Jedoch besitzt der reine 
Arzneistoff eine hohe Zytotoxizität und erfordert somit ein gezieltes und biokompatibles 
Trägersystem. 
Das einleitende Kapitel dieser Arbeit umfasst Konzepte, Modalitäten und Funktionalitäten des 
Projektes. Es findet zunächst eine detaillierte Beschreibung des Zelltyps (dreifach-negativer 
Brustkrebs) statt. Des Weiteren wird die Bedeutung von liposomalem DOX erklärt und der 
aktuelle Forschungsstand aufgezeigt. Die Bedeutung der Modifikation zur Erzielung der 
thermosensitiven Eigenschaften und die Vorgehensweise zur Co-Verkapselung mit Gd-Chelat 
um paramagnetische Eigenschaften zu erreichen wird ebenfalls behandelt. Zudem wird im 
ersten Teil die Oberflächenmodifikation mit ADAM8-Antikörper beschrieben, was zu einem 
verbesserten Targeting führt. 
Der zweite Teil der Arbeit umfasst die verschiedenen Materialien und Methoden, die in der 
vorliegende Arbeit zum Einsatz kamen. Die Herstellung der Liposomen LipTS, LipTS-GD,      
LipTS-GD-CY, LipTS-GD-CY-MAB und die Beladung von DOX unter Verwendung eines 
Ammoniumsulfatgradienten wurden detailliert beschrieben.  
Das erste Kapitel des Ergebnisteils behandelt die physikalisch-chemische Charakterisierung 
mittels dynamischer Lichtstreuung und Laser-Doppler-Velocimetrie, welche eine gleichmäßige 
monodisperse Verteilung der Liposomen bestätigte. Diese Eigenschaften erleichtern die 
Annäherung der Liposomen an die Zielkrebszellen. Der Einfluss der Lipidzusammensetzung 
der Liposomen, der Co-Verkapselung von Gd-Chelat und der Oberflächenmodifikation der 
Liposomen wurde entsprechend bewertet und beschrieben. Größe und Struktur der einzelnen 
liposomalen Formulierungen wurden mit Hilfe der Rasterkraftmikroskopie und Transmission-
selektronenmikroskopie bestimmt. Die morphologische Untersuchung der Liposomen 
bestätigte eine Übereinstimmung mit den Größen, die durch dynamische Lichtstreuung erhalten 
wurden. Temperaturabhängige AFM-Bilder zeigten eine intakte Liposomenstruktur bei 37 °C, 
wohingegen eine Erhitzung durch UHF-MRI, zu einem Lipidfilm führte, der auf die Zerstörung 
der Lipiddoppelschicht hinwies. Des Weiteren zeigten TEM-Bilder die morphologischen 
Eigenschaften der Liposomen und gaben einen genaueren Hinweis wie sich Gd-Chelat 
innerhalb der Liposomen anlagert. Liposomen mit Gd-Chelat zeigten gut getrennte Vesikel, 
96 
 
was darauf hindeutete, dass sich Gd-Chelat in der Lipiddoppelschicht der Liposomen einlagert. 
Gd wurde in den hydrophilen Kern der Liposomen vereingekapselt, wohingegen das Gd-chelat 
in die Lipidmembran ragt. 
Durch dynamische Differenzkalorimetrie und temperaturabhängige Arzneimittelfreisetzung 
konnte die Wärmeempfindlichkeit der Liposomen bestimmt werden. Liposomen zeigten einen 
Beginn der Phasenübergangstemperatur bei etwa 38 °C, was ebenfalls unter UHF-MRT-
Exposition erreicht werden kann. Das Maximum dieser Temperatur lag im Fall von LipTS-GD 
und LipTS-GD-CY-MAB bei 42 und 40 °C. Eine „Proof-of-Concept-Studie“ für die thermosensitiven 
Eigenschaften der Liposomen sowie ein zeitabhängiges DOX-Freisetzungsprofil bei 
Hyperthermie wurde erstellt.  
Gd-Chelat ist sowohl in LipTS-GD als auch in LipTS-GD-CY-MAB enthalten und führte daher zu 
paramagnetischen Eigenschaften dieser Liposomen. Dies ermöglichte die UHF-MRT-
vermittelte DOX-Freisetzung sowie die Diagnostik solider Tumore und metastasierender 
Zellen. Die Änderung der Relaxationsrate R1 der Liposomen wurde vor und nach dem Erhitzen 
über Tm (T> Tm) quantifiziert. Die Relaxivität der Liposomen wurde aus der berechneten 
Steigung der Relaxationsrate gegen die Gd-Konzentration erhalten. Bemerkenswerterweise 
erhöhten sich die Relaxationsrate und die Relaxivität nach dem Erhitzen der Liposomen über 
Tm (T> Tm), was darauf hinweist, dass sich die Liposomen öffneten, Gd-Chelat freisetzten und 
der Austausch von Wassermolekülen schneller und praktikabler wurde. 
Toxizitätsstudien beschreiben die verschiedenen Mechanismen für die induzierte 
DOX-Toxizität. Die stärkere zytotoxische Wirkung bei erhöhten Temperaturen zeigt eine 
thermisch induzierte Toxizität, d.h. es kam zu einer Freisetzung von DOX aus den Liposomen 
bei erhöhter Temperatur. Die Überlebensrate der Zellen bei 37 °C deutet darauf hin, dass die 
Liposomen bei normalen physiologischen Temperaturen intakt waren. Unter 
UHF-MRT-Behandlung wurde eine Zelltoxizität aufgrund einer erhöhten Temperatur erreicht. 
Die Verfolgung der zellulären Aufnahme der Liposomen unter UHF-MRT fand mit Hilfe der 
konfokaler Lasermikroskopie statt. Ein Anstieg der Fluoreszenzintensität wurde nach UHF-
MRT-Exposition beobachtet. Die Untersuchung des Aufnahmewegs zeigte, dass die Mehrzahl 
der Liposomen hauptsächlich durch Clathrin-vermittelte Endozytose aufgenommen wurden. 
Darüber hinaus wurden die Liposomen mit Anti-ADAM8-Antikörper (MAB 1031) modifiziert 
um ein gezieltes Targeting zu ermöglichen. Die zellulären Bindungsfähigkeiten der 
oberflächenmodifizierten und nicht-modifizierten Liposomen wurden auf Zellen getestet, die 
eine ADAM8-Überexpression hatten, sowie auf ADAM8-Knockdown-Zellen. 
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Oberflächenmodifizierte Liposomen zeigten einen signifikanten Anstieg der 
Bindungsfähigkeiten, was auf ein signifikantes Targeting gegen Zellen hinweist, die ADAM8 
auf ihrer Oberfläche überexprimieren. Zusätzlich konnten Zellen mit Knockdown-ADAM8 
keine signifikante Menge an modifizierten Liposomen binden. 
Die Bewertung der Biokompatibilität der Liposomen wurde unter Verwendung eines 
Hämolysetests und einer aktivierten Thromboplastinzeit (aPTT) bestimmt. Liposomen zeigten 
ein vernachlässigbares hämolytisches Potential. Ebenso zeigen aPTT-Studien, dass Liposomen 
die Blutgerinnung nicht stören. Hämokompatibilitätsstudien können helfen, die Korrelation 
zwischen in vitro und in vivo zu verstehen.  
Zur bewertung der systemischen Biokompatibilität wurde das in ovo 
Chorioallantoismembranmodell verwendet, das einen alternativen Tierversuch darstellt. Im 
Toxizitätstest wurden Liposomen intravenös in die Hühnerembryonen injiziert. Die Liposomen 
zeigten eine vernachlässigbar schädliche Wirkung auf die Entwicklung des Embryos. Während 
freies DOX einen schädlichen Effekt auf das Überleben der Hühnerembryonen hatte, dies 
bestätigt das verbesserte Sicherheitsprofil der Liposomen im Vergleich zu freiem DOX. 
LipTS-GD-CY-MAB wurden am Eierentwicklungstag 11 in das Gefäßsystem des Hühnerembryos 
injiziert und unter UHF-MRT gescannt, um die magnetischen Eigenschaften der Liposomen in 
einem biologischen System mit T2-gewichteten Bildern (3D) zu bewerten. Die liposomale 
Formulierung hatte erkennbare magnetische Eigenschaften unter UHF-MRT und das Küken 
überlebte den Scan. 
Zusammenfassend lässt sich sagen, dass immunomagnetische wärmeempfindliche Liposomen 
eine neuartige Arzneiform zur TNBC-Behandlung darstellen könnte. Sie dient sowohl zur 
Diagnose als auch zur Therapie von soliden und metastasierenden Tumore ohne 
Nebenwirkungen auf das Nachbargewebe zu haben. 
Das weitere Vorgehen besteht darin einen Tumor im CAM-Modell zu etablieren, das selektive 
Targeting der Liposomen zu visualisieren und mittels Fluoreszenz sowie UHF-MRT zu 
quantifizieren. Ebenso müssen die Liposomen an Mäusen als dreifach-negatives 
Brustkrebsmodell im Xenograft-Verfahren getestet werden, um weitere Wirkungen von DOX-
LipTS-GD-CY-MAB zu untersuchen. Zum einen sollen die Liposomen hinsichtlich ihrer Zielbarkeit 
und ihrer selektiven Bindung bewertet werden. Andererseits wird die ausgelöste Freisetzung 
von DOX aus den Liposomen nach UHF-MRT-Exposition und die therapeutische Wirkung von 
DOX-Liposomen auf den Tumor bewertet. 
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